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RIASSUNTO 
Il cancro ereditario non poliposico del colon-retto, noto anche come 
Sindrome di Lynch, rende conto di circa il 3-5% dei tumori colorettali 
sporadici; è una sindrome ereditaria autosomica dominante, associata 
a mutazioni germinali nel complesso dei geni del riparo di 
appaiamenti errati di basi del DNA (MisMatch Repair, MMR). La 
perdita di funzione di una o più di queste proteine a livello germinale 
determina una significativa instabilità genomica a livello somatico, 
specie a carico di sequenze ripetute (microsatelliti) presenti in molti 
oncogeni e oncosoppressori, accelerando così il processo di 
tumorigenesi. Ciò si traduce in una più precoce età di insorgenza della 
malattia (circa 45 anni) rispetto ai casi sporadici di cancro del colon. 
Tale sindrome presenta una predisposizione al tumore non solo del 
colon, ma anche di altri organi quali endometrio, stomaco, ovaie, 
piccolo intestino, epitelio epatobiliare, epitelio uroepiteliale e cervello. 
Alla base di questa variabilità fenotipica esisterebbe un’interazione tra 
geni principali (MMR) e geni modificatori e/o fattori ambientali. 
I geni MMR maggiormente coinvolti sono MLH1 e MSH2, che 
risultano mutati rispettivamente nel 40% e 39% dei casi HNPCC, 
mentre mutazioni nei geni MMR cosiddetti”minori”, MSH6, PMS2, 
MLH3 e MSH3, rendono conto complessivamente del 21% dei casi, 
con un maggiore contributo del gene MSH6 (11%). 
L’iter diagnostico comunemente utilizzato prevede la ricerca di 
mutazioni puntiformi, mediante DHPLC e diretto sequenziamento, e 
di ampi riarrangiamenti, mediante MLPA, nei geni principali MLH1 e 
MSH2, per la caratterizzazione molecolare di soggetti con diagnosi 
clinica di Sindrome di Lynch. Tuttavia, tale indagine non sempre 
fornisce risultati informativi ai fini della consulenza genetica. Infatti, 
nel nostro laboratorio, negli ultimi 5 anni, su 117 famiglie con 
predisposizione ereditaria allo sviluppo del tumore, selezionate in base 
a criteri diagnostici internazionali (Criteri di Amsterdam, Lynch HT et 
al, ICG-HNPCC, Gastroenterology 1999, e Linee Guida di Bethesda, 
Umar et al, J Natl Cancer Inst., 2004), 64 sono risultate senza una 
chiara diagnosi molecolare, per assenza di mutazioni nei due geni 
principalmente investigati, o per la presenza in tali geni di varianti di 
dubbio significato patogenetico (VUS, Variants of Uncertain 
Significance) (varianti missense, introniche e silenti). I soggetti 
appartenenti a tali famiglie, di cui 40 rispondenti ai Criteri di 
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Amsterdam e 24 alle Linee Guida di Bethesda, sono stati selezionati 
per più estese indagini molecolari. 
Al fine di valutare il significato patogenetico di varianti VUS, sono 
stati utilizzati diversi approcci sperimentali quali analisi di 
segregazione, studi di popolazione, valutazione di instabilità genomica 
(MSI, instabilità di sequenze Microsatelliti) nel tessuto tumorale, 
identificazione di perdita di eterozigosità (LOH) nel tessuto tumorale, 
analisi quantitativa di trascritti e di prodotti proteici ed infine analisi 
bioinformatiche. La combinazione di più risultati concordanti tra di 
loro ha facilitato l’interpretazione del significato patogenetico delle 
varianti analizzate, secondo le linee guida riportate in letteratura 
(Colon Cancer Family Registry 2009, InSiGHT Variant 
Interpretatioin Committee 2011). 
In particolare, è stato approfondito lo studio di quattro VUS, di cui tre 
identificate nel gene MLH1 e una nel gene MSH2, in quanto associate 
a fenotipi clinici piuttosto severi, e spesso segreganti con la malattia 
nelle famiglie portatrici di tali varianti.  
Molto interessante è risultato lo studio delle due mutazioni identificate 
nelle regioni 3’UTR dei geni MMR (c*30_32delTTC nel gene MLH1 
e c*226A>G nel gene MSH2). In particolare, la c*30_32delTTC, 
riportata come variante benigna nel database dei geni MMR (Insight-
group database), sulla base dei nostri risultati, è risultata determinare 
un abbassamento nei livelli sia del trascritto genico che del suo 
prodotto proteico. I risultati ottenuti sono in accordo con recenti dati 
di letteratura in base ai quali la regione in cui cade la mutazione è stata 
identificata quale putativo sito target del miRNA miR-422a (Mao et 
al., J Biol Chem, 2008). Più recentemente, è stato anche dimostrato un 
meccanismo di regolazione a feedback tra MLH1 e miR-422a  (Mao 
et al., Cell Res, 2012). È interessante notare che tale mutazione, nei 
casi di fenotipo più aggressivo, è stata da noi identificata sempre in 
associazione con un’altra variante, la c.454-51t>c. Pertanto, abbiamo  
ipotizzato anche un probabile effetto additivo patogenetico tra queste 
due alterazioni geniche. 
La variante nel gene MSH2, la c*226A>G, anch’essa già descritta in 
letteratura e riportata come variante benigna, nella famiglia da noi 
identificata è risultata associata con la malattia. Inoltre, in questa 
famiglia abbiamo osservato l’associazione anche con condizioni 
morbose diverse dalla Sindrome di Lynch, come il Linfoma di 
Hodgkins. I nostri risultati hanno mostrato un incremento nei livelli 
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sia del trascritto che della proteina. In seguito a tali risultati, al fine di 
chiarire il meccanismo molecolare alla base dell’iper-espressione da 
noi osservata, è stata effettuata un’analisi in silico mediante i 
programmi di predizione di zone target di miRNA (TargetScan e 
miRanda) e di fattori di regolazione trascrizionale (TRANSFAC). La 
regione in cui cade la mutazione è stata identificata quale putativo sito 
target di due miRNA (hsa-miR-137, hsa-miR47953p), e di quattro 
fattori di regolazione trascrizionale, ZNF333, POU6F1, CDP e PMX1, 
con principale ruolo di repressori trascrizionali. Pertanto, abbiamo 
ipotizzato che tale variante, impedendo il legame della regione 3’UTR 
di MSH2 con tali fattori, possa determinare una incontrollata 
espressione del trascritto e del relativo prodotto proteico. I risultati 
ottenuti sono stati da noi confermati mediante saggio funzionale di 
espressione di luciferasi che hanno mostrato un aumento dei livelli di 
espressione in presenza di tale variante, supportando quindi alcuni dati 
di letteratura che mostrano come anche l’iper-produzione delle 
proteine del mismatch repair possa essere considerata deleteria (Zhang 
H. et al., Cancer Res 1999; Shcherbakova PV. et al., Mol. Cell. Biol., 
2001). I risultati ottenuti per la variante c*226A>G nel gene MSH2 
sono a favore di un possibile ruolo patogenetico nello sviluppo della 
malattia. 
L’attività di ricerca è proseguita con l’identificazione di varianti nei 
geni minori del mismatch repair, per quei pazienti risultati negativi per 
qualsiasi tipo di alterazione nei geni maggiori, MLH1 e MSH2. Infatti, 
alla luce di recenti studi che hanno dimostrato come il sistema MMR, 
oltre alla riparazione post-replicativa, svolge altri ruoli altamente 
rilevanti nella carcinogenesi, come il controllo del ciclo cellulare e del 
processo apoptotico (Jiricny J. et al. Mol Cell Biol 2006, Ji et al., 
BMC Med 2012, Mao G., et al., Cell Res, 2012), è ipotizzabile che in 
questi nuovi ruoli siano coinvolti anche i geni MMR minori. Oltre a 
varianti di certo significato patogenetico (due mutazioni frameshift ed 
un’inserzione in frame nel gene MSH6, un’ampia duplicazione nel 
gene PMS2 ed una mutazione troncante nel gene MLH3) identificate 
in questo studio, e varianti la cui patogenicità è stata già descritta in 
letteratura (cinque mutazioni missense nel gene MSH6), un cospicuo 
numero di VUS, circa 70, sono state ritrovate anche nei geni minori. 
Pertanto, una dettagliata caratterizzazione fenotipica, come descritto 
sopra per i geni MLH1 e MSH2, è stata effettuata anche per alcune di 
tali varianti, allo scopo di classificarle come patogenetiche. E’ 
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risultato interessante notare come molti tra i soggetti analizzati 
presentano multiple alterazioni geniche in più geni MMR, a sostegno 
dell’ipotesi di un’ereditarietà complessa, di tipo poligenico, per la 
Sindrome di Lynch (Duraturo F. et al. Int J Cancer 2011) che è stata 
sollevata sulla base di recenti studi su genoma di lievito (Martinez SL. 
et al. PNAS, 2010, Kumar C. et al. Mol Biol, 2011). Purtroppo, per la 
scarsa collaborazione dei soggetti analizzati, solo per una delle 64 
famiglie studiate è stato possibile verificare in maniera completa come 
l’associazione simultanea di più varianti VUS identificate sia nei geni 
MMR major che in quelli minor, segregava perfettamente con la 
malattia. L’ipotesi di un effetto sinergico tra alleli a bassa penetranza 
spiegherebbe anche la mancata segregazione osservata per le due 
varianti di certo significato patogenetico identificate nel gene MSH6, 
c.3261_62insC e c.3296_97 delTT. Infatti, solo in alcuni dei membri 
affetti delle famiglie analizzate queste due mutazioni sono state 
trovate associate a varianti negli altri geni minori. Inoltre, non si 
esclude la concomitante presenza di alterazioni in altri geni pur 
implicati nel processo di carcinogenesi, non investigati in tale studio.  
In conclusione, l’attività scientifica svolta ha consentito in primo 
luogo di chiarire meglio le correlazioni genotipo-fenotipo nella 
Sindrome di Lynch, dimostrando l’importanza di un approccio 
analitico multidisciplinare, anche al fine di comprendere i meccanismi 
molecolari alla base di fenotipi-malattia non canonici; in secondo 
luogo, sono state messe in luce nuove prospettive diagnostiche per la 
Sindrome di Lynch, che si discostano dalla classica trasmissione 
monogenica, a favore dell’ipotesi di un modello di ereditarietà di tipo 
poligenico, anche se ulteriori studi sono necessari per avvalorare tale 
ipotesi. 
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SUMMARY 
The Hereditary Non-Polyposis Colorectal Cancer (HNPCC), also 
known as Lynch Syndrome (LS), is an autosomal dominantly 
inherited cancer syndrome that accounts for about 3-5% of all 
colorectal cancers (CRCs). It is commonly associated with germline 
mutations in the mismatch repair (MMR) genes. The loss of function 
of one or more of these proteins results in a significant genomic 
instability at somatic level, particularly in repetitive DNA sequences 
(microsatellites) present in many oncogenes and tumor suppressor 
genes. This mutator phenotype promotes the tumorigenesis process 
that justifies the earlier age of onset of the disease (approximately 45 
years). LS is characterized by high lifetime risk for tumor 
development, especially CRC, endometrial cancer and other 
extracolonic tumors. These extra-colonic malignancies include 
carcinomas of the small intestine, stomach, pancreas, biliary tract, 
ovarium, upper urinary tract and brain.  
The MLH1 and MSH2 mutations account for about 40% and 39% of 
HNPCC cases, respectively, while mutations in minor MMR genes, 
MSH6, PMS2, MLH3 and MSH3, justify a total of 21% of cases, in 
which the MSH6 gene gives a greater contribution (11%). 
The molecular characterization of patients with a clinical diagnosis of 
Lynch Syndrome relies on the identification of point mutations by 
DHPLC and direct sequencing, and large rearrangements by MLPA, 
in the major MMR genes, MLH1 and MSH2.  
This strategy does not always provide exaustive information for 
genetic counseling. Indeed, we analyzed 117 families selected 
according to international diagnostic criteria (Amsterdam Criteria, 
Lynch HT et al, ICG-HNPCC, Gastroenterology 1999 and Bethesda 
Guidelines, Umar et al, J Natl Cancer Inst., 2004). Molecular 
diagnosis was achieved for 53 families while no MLH1/MSH2 
mutations were identified in the remaining 64 families. Moreover, we 
identified genetic variants of uncertain significance (VUS) (missense, 
intronic and silent variants) in several other patients.  
Therefore, in this study we have characterized the VUS that we had 
identified in the major MMR genes, in order to classify them as 
pathogenic, using the following approaches: segregation analysis, 
population studies to exclude the polymorphic nature of the variant, 
assessment of Microsatellite Instability (MSI), gene expression studies 
both at mRNA and protein levels and in silico analysis with a variety 
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of bioinformatics tools such as HSF (Human splicing Finder), 
PolyPhen (Polymorphism Phenotyping), SIFT (Sorting Intolerant 
From Tolerant), and PredictProtein.  
According to literature data (Colon Cancer Family Registry in 2009, 
Insight Variant Interpretatioin Committee 2011), a combination of 
these strategies has been used for each variant in order to assess the 
pathogenicity of uncertain variants. 
We performed phenotypic and functional characterization of some of 
the most interesting variants of uncertain significance identified (three 
variants in the MLH1 gene and one in the MSH2 gene) that were 
associated with severe disease phenotypes.  
In particular, the study of two mutations detected in the 3’untranslated 
regions (3'UTR) of the MLH1 and MSH2 genes (c*30_32delTTC in 
the MLH1 gene and c*226A>G in the MSH2 gene) gave very 
interesting results.  
The c*30_32delTTC was reported as a benign variant in the MMR 
gene variants database (Insight-group database). Our results showed 
lower levels both at RNA and protein levels. These data are in 
agreement with recent literature studies reported on this variant (Mao 
G. et al., J Biol Chem, 2008). In particular, the region in which falls 
the mutation has been identified as a putative target point of the miR-
422a and a mechanism of feedback regulation between MLH1 and this 
miRNA was also demonstrated (Mao G. et al., Cell Res, 2012). In our 
study, in more aggressive phenotypes, this mutation has always been 
identified in association with another variant, the c.454-51t> c. 
Therefore, a likely pathogenetic additive effect between these two 
genetic alterations could be proposed.  
The multivariate analysis of the other 3’UTR variant, the c.*226A>G 
in MSH2 gene, also provided very interesting data in order to assess 
the correlation with the disease phenotype. In our study, this variant 
was found associated with both typical Lynch Syndrome features 
(colorectal and endometrial tumors) and atypical phenotypes such as 
Hodgkin Lymphoma. This analysis showed increased mRNA and 
protein levels, as also confirmed by a functional luciferase assay. In 
order to clarify the molecular mechanism at the basis of this over-
expression, in silico analysis was performed for prediction of miRNA 
target sites (TargetScan and MiRanda) and transcriptional regulation 
factor binding sites (TRANSFAC). The region in which falls the 
mutation is identified as a putative target point of two miRNAs (hsa-
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miR-137, hsa-miR47953p), and four trans-acting protein factors, 
ZNF333, POU6F1, CDP and PMX1, known also as transcriptional 
repressors. Therefore, we hypothesized that this variant could prevent 
the binding of these factors with the MSH2 3'UTR leading to 
unregulated expression of the MSH2 gene. In agreement with several 
literature data showing a deleterious effect derived from 
overproduction of MMR proteins (H. Zhang et al., Canc Res 1999; 
Shcherbakova PV. et al., Mol. Cell. Biol., 2001 ), it is conceivable that 
the variant c.*226A> G in the MSH2 gene has a pathogenic role in the 
development of the disease.  
In our study we also analyzed the minor MMR genes, MSH6, PMS2, 
MLH3 and MSH3, for the presence of germline variants in patients 
who had been resulted to be negative for germline mutations in the 
major MMR genes. Recently, literature data suggest that the MMR 
proteins, including the minor MMR factors, may have other functions 
in cell cycle and apoptosis regulation, in addition to the post-
replicative repair role, that could be highly relevant for the 
carcinogenesis process  (Jiricny J. et al. Mol Cell Biol 2006, Ji et al., 
BMC Med 2012, Mao G., et al., Cell Res, 2012). According to these 
data, we undertook a mutational analysis on the minor MMR genes 
and were able to identify 77 variants, five of which were pathogenic 
mutations, 5 missense variants already described in the literature as 
pathogenic mutations and 67 unclassified variants (missense, silent 
and intronic variants). A detailed phenotypic characterization, as 
described above for the MLH1 and MSH2, was also carried out for 
some of these variants, in order to classify them as likely 
pathogenetic. The most relevant result of this mutational analysis on 
minor MMR genes was the simultaneous presence of multiple 
molecular alterations in different genes or in a single gene in several 
unrelated patients. We proposed that some (or all) of these variants 
could constitute low penetrance alleles, with an additive effect on the 
risk of the disease (Duraturo F. et al., Int J Cancer 2011). This 
hypothesis is confirmed by an exhaustive molecular analysis 
performed for one of the 64 subjects analyzed in this study. Two 
literature studies on the yeast genome also demonstrated our 
hypothesis (Martinez SL. et al. PNAS, 2010, Kumar C. et al. Mol Biol, 
2011). The probability of a synergistic effect between low-penetrance 
alleles could also explain the loss of segregation observed for two 
pathogenetic variants identified in the MSH6 gene, c.3261_62insC 
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and c.3296_97 delTT. These two mutations have been found 
associated with variants in other minor MMR genes in some of 
affected members of the families analyzed. Moreover, we can not 
exclude the concomitant presence of alterations in other genes 
involved in carcinogenesis but not investigated in this study.  
In conclusion, this study allowed to clarify the genotype-phenotype 
correlations in Lynch syndrome, demonstrating the importance of a 
multifactorial likelihood analytical approach, also in order to 
understand the molecular mechanisms that regulate the MMR protein 
and their putative prognostic and therapeutic implications in Lynch 
Syndrome. Moreover, the simultaneous presence of molecular 
alterations in several genes (major and minor MMR genes) could 
suggest an additive effect of these mutations in cancer predisposition, 
against the classical monogenic transmission and in favor of a 
polygenic inheritance, although further studies on other familial cases 
will be needed to confirm this hypothesis. 
.  
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Introduction 
1. INTRODUCTION 
 
1.1 Inherited colorectal cancer syndromes 
Colorectal cancer (CRC) is a multifactorial disease in which genetic 
and environmental factors are involved. 
CRC is extremely common as reflected by its worldwide annual 
incidence of 1.2x106 cases. Familial CRC, in which one or more first-
degree and/or second degree relatives of the index case manifest CRC, 
constitutes approximately 20% of the total CRC burden (248,000 
cases worldwide) (Lynch H.T., 2014). 
High penetrance mutations confer a predisposition to CRC in the so-
called hereditary syndromes, responsible for about 2-6% of the total 
CRC. Low-penetrance mutations are found in the remaining part of 
CRC (about 96%), representing a risk factor in both sporadic and 
familial cases (Chang CC., 2011, Valle L, 2014).  
CRC syndromes are defined on the basis of clinical, pathological and, 
more recently, genetic findings (Valle L., 2014) (Tab. 1). 
Accordingly, the identification of predisposing genes allows for 
accurate risk assessment and more precise screening approaches.  
Lynch syndrome (LS) is by far the most common hereditary form of 
CRC with an incidence of 3-5% of all CRCs whereas its primary 
genetic counterpart, namely Familial Adenomatous Polyposis (FAP), 
accounts for less than 1% of the total CRC burden (Lynch H.T., 2014) 
(Fig.1). 
 
 
Figure 1. Distribution of the different types of colorectal cancer (Lynch et al., Curr 
Treat Option Oncol, 2014) 
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Introduction 
HNPCC and FAP are diseases with autosomal dominant inheritance, 
caused by germline mutations in the DNA Mismatch Repair genes 
(MMR), or in the Adenomatous Polyposis Coli tumor suppressor gene 
(APC), respectively. These syndromes may also occur in more 
attenuated forms. In FAP syndrome, attenuated forms (AFAP) are 
caused by low penetrance mutations (missense mutations) in the main 
APC gene or by biallelic loss of the MYH gene (MAP, MUTYH-
associated polyposis with autosomal recessive inheritance), encoding 
a protein of the Base Excision Repair complex (BER). 
Variant forms of HNPCC are characterized by the presence of 
additional tumors in extra-colonic locations of still unclear etiology. 
Recent studies suggest that an interaction between main genes (MMR) 
and modifier genes and / or environmental factors may be at the basis 
of these tumors. These variant syndromes include Muir-Torre 
syndrome (autosomal dominant) due to MSH2 and MLH1 genes 
mutations and characterized by the presence of cutaneous 
manifestations (multiple sebaceous adenomas, epithelioma, 
keratoacanthoma) associated with colorectal and endometrial cancers; 
Turcot syndrome (autosomal dominant) associated with APC, PMS2 
and MLH1 genes mutations, wherein brain cancers (glioblastoma and 
cerebellar medulloblastoma) are associated with colorectal cancer 
(Sammader NJ., 2014). 
More recently, gastric cancers have been included in the tumor 
spectrum of HNPCC. The molecular and clinicopathological profiles 
of gastric cancers in HNPCC mutation carriers have been evaluated 
and compared with the profiles of sporadic gastric cancers, and 
several differences have been identified, while there were similarities 
with canonical HNPCC spectrum malignancies. Stomach can thus be 
considered as a target tissue where somatic inactivation (“second hit”) 
of MMR genes may occur in carriers of a germline mutation (“first 
hit”) (Corso G., 2011; Gylling A.,2007). 
In the process of colorectal carcinogenesis many other genes are 
involved such as oncogenes and tumor suppressor genes that play a 
key role in the control of cell cycle. Mutations in these genes are at the 
basis of rarer inherited CRC syndromes. These are mainly 
"hamartomatous polyposis syndromes" characterized by the presence 
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of benign adenomas arising from epithelial and / or stromal intestinal 
tissue, which increase the risk of developing CRC. These syndromes, 
whose characteristics are summarized in Table 1, include Peutz-
Jeghers syndrome, juvenile polyposis, Cowden syndrome and 
Bannayan-Riley-Ruvalcaba syndrome (Jelsig AM., 2014, Stoffel EM., 
2015). 
 
 
 
Table 1. Hereditary colon cancer syndromes: clinical and genetic features 
(AD, autosomal dominant; AR, autosomal recessive). 
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1.2 Lynch Syndrome 
The characterization of families affected by hereditary colon cancer 
was described for the first time in 1913 by Warthin. In 1966, Lynch 
and his colleagues described two families who had colorectal cancer 
associated with endometrial and gastric cancers. This syndrome is 
known with the term of HNPCC (Hereditary Non-Polyposis 
Colorectal Cancer) to highlight the absence of colon polyps and 
distinguish this syndrome from other hereditary forms of colorectal 
cancer such as familial adenomatous polyposis (FAP) (Peltomaki P., 
2001; Weitz J., 2005; Olschwang S., 2006). 
Hereditary non-polyposis colorectal cancer (HNPCC), also known as 
Lynch syndrome (LS), accounts for about 3-5% of sporadic colorectal 
cancers (CRCs); it is an autosomal dominant condition with recessive 
phenotype caused by a defect in one of the mismatch repair (MMR) 
genes. 
The main features of the Lynch syndrome are listed in Table 2 (Lynch 
HT., 2014; val Lier MGF., 2010). 
 
Autosomal dominant inheritance; 
Penetrance for colorectal cancer (CRC) of 85-90%; 
Earlier age of onset of CRC (~ 45 years ) with respect to general population  
(69  years); 
Preferential tumor localization in the right-sided colon; 
Presence of multiple synchronous and metachronous colorectal cancers; 
Better prognosis than CRCs; 
Increased risk for extra-colonic cancers; 
Accelerated carcinogenesis; 
Poorly differentiated tumors, with a marked lymphocytic peritumoral 
inflammation recalling features of the so-called "Crohn's reaction"; 
Microsatellite instability 
 . 
Table 2. Clinical-pathological features of Lynch syndrome. 
 
LS patients present a germline mutation in one of the MMR genes and 
acquire inactivation of the second wild-type allele in their tumors, 
fulfilling the Knudson’s two hit hypothesis for inactivation of tumor 
suppressor genes. Somatic inactivation of the corresponding wild-type 
allele occurs almost exclusively through point mutations or (partial) 
gene loss; bi-allelic inactivation then leads to complete abolition of 
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the protein function. This results in a defective DNA MMR system, 
since the MMR proteins are involved in the correction of single 
nucleotide mismatches and small insertions or deletions that may arise 
during DNA replication (Lawes DA.,2002). 
The mechanism of the MMR complex has been largely elucidated  
and is depicted in Fig. 2. 
 
 
 Figure 2. The human Mismatch repair system (From Clin Cancer Res., 2012, 
18(6): 1506-1512). 
 
The mismatch repair system was first studied in bacteria in which 
three proteins, MutS, MutL and MutH, were identified. In humans, at 
least seven mismatch repair genes are involved in mismatch repair and 
their names derive from their structural homology to the bacterial 
proteins: the MutS homologues (MSH), MSH2 on chromosome 2p16, 
MSH3 on chromosome 5q11, and MSH6 on chromosome 2p16; the 
MutL homologues (MLH), MLH1 on chromosome 3p21, and MLH3 
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on chromosome 2p16; and post-meiotic segregation homologues 
(PMS), PMS1 and PMS2 on chromosome 7p22. No MutH 
homologues have been identified in humans (Hegan DC., 2006). 
MSH2 and MSH6 bind together to form a heteroduplex (MutSα) that 
predominantly identifies single base mispaires, while MSH2 and 
MSH3 (MutSβ) combine to identify short insertions or deletions. 
MSH2 is essential for both complexes to function, while a functional 
overlap exists between MSH3 and MSH6. MLH1 and PMS2 (MutLα) 
or MLH3 (Mutlγ) also bind together to form a heteroduplex that 
interacts with MutSα or MutSβ complex, stimulating excision and 
resynthesis of the abnormal DNA. Similarly to MSH2, also MLH1 is 
essential for both complexes to repair mismatches. Altogether, this 
group of four proteins recruits exonuclease-1 (EXO1), the 
proliferating cell nuclear antigen (PCNA), DNA polymerase (Pol δ or 
Pol ε), two replication factor (RPA and RFC), and a ligase, to repair 
DNA on the daughter strand at the mismatch point. If any of the four 
major proteins (MSH2, MLH1, MSH6, or PMS2) is functionally 
inactive, mismatches are not repaired (Jun S., 2006, Jirincy J., 2006).  
Consequently, a defective DNA MMR system increases the mutation 
rate and makes the cell vulnerable to mutations in genes controlling 
cell growth (tumor suppressor genes and oncogenes), resulting in an 
increased cancer risk. 
In case of a defective MMR system, mutations occur frequently in 
small (usually mononucleotide or dinucleotide) repetitive DNA 
sequences, known as microsatellites. In MMR-deficient tumor cells 
the number of microsatellite repeat units can deviate from the 
corresponding normal DNA; the number of repeats is usually 
decreased even though it is occasionally found increased (Sinicrope 
FA, 2012). 
Length or size microsatellite variation is known as MSI (microsatellite 
instability). MSI (formerly referred to as MIN, or RER, replication 
error) is the molecular hallmark of LS since approximately 95% of all 
LS-associated cancers show MSI (val Lier MGF, 2010). Although 
most microsatellite sequences are located in non-coding sequences 
(telomeres and centromeres), many genes contain repetitive sequences 
in their coding regions and some of these genes play key roles in the 
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regulation of cell growth (Pedestrians M., 2001). In fact, mutations in 
the TGFβRII and TCF-4 genes, that normally inhibit cell growth, and 
in the IGF-RII and BAX genes involved in the apoptotic process 
(Wang.Y., 1997), particularly predispose to colon cancer. Moreover, 
the presence of polyadenine traits in the coding sequences of the 
minor mismatch repair genes, MSH6, MLH3 and MSH3, makes the 
same MMR genes targets of the MIN phenotype (Loukola A., 2000; 
Plaschke J., 2004). Identification of an even growing number of guide 
genes and target genes of the mutator phenotype can lead to discover 
new complex molecular mechanisms that underlie the process of 
colorectal tumorigenesis (Alhopuro P, 2011). 
MSI thereby serves as a reliable phenotypic marker of MMR 
deficiency in order to pre-select patients eligible for germline 
mutation analysis in the MMR genes (Zaanan A., 2011). 
However, despite the fact that MSI is a reliable marker for MMR 
deficiency, its specificity for LS is low since 15% of sporadic CRCs 
also display an MSI phenotype. This is mainly caused by somatic 
hypermethylation of the MLH1-gene promoter. Methylation of the 
MSH2 promoter has also been reported but it is to be considered as a 
heritable somatic methylation because it is caused by a deletion of the 
last exon of EPCAM that is adjacent to MSH2 on chromosome 2 
(Sinicrope FA., 2012). 
Hypermethylation of CpG islands in the MLH1 promoter (CIMP 
phenotype) causes severe inhibition of gene transcription thereby 
mimicking an inactivating gene mutation. If both copies of the gene 
are inactivated (bi-allelic hypermethylation), the MLH1 function is 
lost. This leads to microsatellite unstable cancers, especially in older 
patients. Therefore, in MLH1-deficient microsatellite-unstable tumors 
MLH1 hypermethylation can be assessed to distinguish sporadic 
CRCs from LS-related cancers. Moreover, recent findings have also 
identified the BRAF gene as a marker to distinguish LS from sporadic 
cases of colon cancer (Imai K., 2008; Sharma, 2010). It encodes a 
serine-threonine kinase involved in the activation of Ras/Raf/MEK 
signaling cascade. Specific activating mutations in the BRAF 
oncogene, usually the V600E missense mutation, can be detected in 
40–87% of all sporadic microsatellite unstable tumors (van Lier 
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MGF., 2010). An oncogenic BRAF mutation has been described only 
in one case among several LS tumors (Wang. L., 2003) 
These results indicate that in cases of MSI with suspicion of HNPCC 
BRAF mutations closely correlate with MLH1 promoter methylation 
in sporadic MSI CRCs, in contrast with germline mutations in the 
MMR genes (Fig.3).  
 
 
Figure 3. Two molecular pathways can lead to CRC with MSI. (From Clin Cancer 
Res., 2012, 18(6): 1506-1512). 
 
In 1997 the National Cancer Institute recommended a panel, known as 
the "panel of Bethesda," comprising five microsatellites: two 
mononucleotide repeats (BAT25, BAT26) and three dinucleotide 
repeats (D2S123, D17S250, D5S346) (Boland CR., 1998). Tumors 
showing instability at two or more of these repeats (40% of markers) 
are defined at high instability (MSI-H); those with instability between 
20-40% are classified as low instability (MSI-L) (Vilar E., 2014); 
tumors without alteration (20% or less) are classified as stable (MSS). 
Subsequently, in order to improve the sensitivity rate and the 
predictive specificity, Bethesda guidelines were revised and other loci 
were enclosed in the panel test: BAT-25 and BAT-26 besides three 
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other quasi-monomorphic mononucleotide repeats, namely NR21, 
NR22 and NR24 (Xicola RM., 2007, Humar A., 2004; Suraweera N., 
2002). 
MSI testing is also very important because several evidences suggest 
that MSI-H tumors (stage II) are associated with a favorable prognosis 
when patients are not treated with 5-fluorouracil compared to MSI-L 
and MSS CRC (Sargent DJ., 2010, Kim JH., 2014). These different 
features are probably related to the lymphocytic infiltrate 
characteristic of MMR-deficient tumors that determines an antitumor 
immune response which may be abrogated by the immunosuppressive 
effects of the chemotherapy (Sinicrope FA., 2012).  
Besides MSI testing, analysis of MMR protein expression by 
immunohistochemistry (IHC) is routinely performed to identify 
patients with suspected Lynch syndrome. IHC testing is a specific 
(100%) and sensitive (92,3%) screening tool to identify MSI-H 
tumors (van Lier MGF., 2010; Kheirelseid EA., 2013). 
In conclusion, LS is characterized by a high lifetime risk for tumor 
development, especially in the case of CRC (20–70%), endometrial 
cancer (15–70%) and other extracolonic tumors (15%). These extra-
colonic malignancies include carcinomas of small intestine, stomach, 
pancreas and biliary tract, ovarium, brain, upper urinary tract and skin.  
Identification of MMR gene mutation carriers is critical for improving 
cancer surveillance and effectiveness of prevention. Before MMR 
genes and their causal role in hereditary CRC cancer were identified, 
the International Collaborative Group on hereditary non-polyposis 
colorectal cancer had established the Amsterdam criteria I in 1990. 
These criteria were used to identify families eligible for molecular 
analysis. Subsequently modified guidelines (Amsterdam criteria II) 
were designed to include extracolonic LS-related cancers (Tab. 3). 
Nevertheless, Amsterdam criteria resulted to be very restrictive and 
failed to identify a large portion of MMR gene mutation carriers. To 
overcome this issue, Bethesda guidelines, which were less restrictive 
and had a sensitivity greater than 90% even with a lower specificity 
(25%), were later defined (Tab.4). 
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Table 3. The Amsterdam Criteria 
 
 
Table 4. The Bethesda Guidelines 
 
 
 
 
10 
Introduction 
1.3 New insights into the molecular features of Lynch Syndrome 
Recent data suggest that, in the course of evolution, in addition to the 
post-replicative repair, MMR proteins have developed various other 
functions that are highly relevant in carcinogenesis (Jiricny J., 2006). 
These new roles include:  
1. DNA damage signaling caused by exogenous carcinogens 
(heterocyclic amines, oxidative agents and UV radiation) that is 
achieved through a synergistic action between the p53-homologous 
proteins (p53, p63 and p73) and the MutSα-MutLα complex; 
furthermore, in response to an exogenous damage, MLH1 interacts 
with the protein MRE11, a component of the "BRCA1 associated 
surveillance complex" (BASC), and regulates the cell cycle and the 
apoptotic pathway (O 'Brein V., 2006; Yamake K., 2007); 
2. prevention of reparative recombination (gene conversion) between 
non-identical sequences; (Nicholson S., 2000; Zhang J., 2006); 
3. promotion of meiotic crossover; several studies in S. Cerevisiae and 
knock-out mice have shown that homologous chromosome 
recombination during meiosis is controlled by MMR proteins, in order 
to avoid mutational events due to deletions, insertions or mismatched 
bases. Among the MMR proteins, MLH1, PMS2 and MLH3 are 
involved in this process. In fact, experimental murine deficiency of 
one of these three proteins is associated with male infertility (defective 
spermatogenesis) (Cannavo E., 2005, Ji G., 2012).  
4. immunoglobulin diversification based on the ''somatic 
hypermutation "(SHM) process, which is regulated by the MutSα-
MutLα complex, in combination with two other proteins, AID 
(activation-induced cytidine deaminase) and pol η (DNA Polymerase 
"error-prone") (Wiesendanger M., 2000; Li Z., 2006, Jiang C, 2012); 
in particular, MutSα deficiency is associated with neoplastic 
transformation of T lymphocytes (Roa S., 2010). 
5. expansion of repeated triplets (CTG, CGG) that underlie the 
pathogenesis of various neurodegenerative diseases such as 
Huntington's Disease, Myotonic Dystrophy and Fragile X Syndrome. 
This mechanism is still unknown, however experimental evidences 
indicate that, although MutSβ binds these expansions, the repair is 
prevented by looping conformations of these regions (Tome S., 2009). 
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Since the triplet expansion is at the basis of the anticipation of the 
disease in the family, loss of function of MutSβ may have a protective 
role against the intergenerational instability (Dragileva E., 2009; 
Seriola A., 2011). 
6. modulation of microRNA biogenesis by interaction of MMR 
proteins with the Microprocessor complex; in particular, MutLα 
specifically binds to pri-miRNAs and to the complex Drosha/DGCR8 
in order to stimulate the processing of pri-miRNAs to pre-miRNAs in 
a manner dependent on MutLα ATPase activity (Mao G, 2012). 
These new features indicate that MMR deficiency strongly affects 
cellular resistance to reparative and/or apoptotic response to DNA 
damage because impairment of post-replicative MMR complex is 
associated with impairment of components of other cell systems. 
 
1.4 Genotype-phenotype associations in Lynch syndrome: 
Canonical features 
Until now, about 500 different mutations have been identified in the 
MMR genes that predispose to HNPCC (www.insight-group.org). 
Germline mutations in MLH1, MSH2 and MSH6 account for 
approximately 40%, 39% and 11%, respectively, of all the mutations 
reported whereas PMS2, MLH3 and MSH3 contribution to cancer 
onset is less significant (Desai TK., 2008). 
An updated list of the mutations identified has been published by the 
International Collaborative Group on HNPCC (www.insight-
group.org site), enclosing 256 mutations in MLH1, 249 in MSH2, 70 
in MSH6, 13 in PMS2 and 11 in MLH3. 
Mutations are distributed unevenly along each MMR gene, denoting 
the absence of mutational "hot spot" events. Even the nature of the 
germline alterations is varied. 
Absence of redundant functions for MSH2 and MLH1 proteins 
stresses the importance of these two genes; therefore, mutations in 
these genes are associated with aggressive forms of HNPCC, 
characterized by early age of onset, typically around 45 years of age, 
high penetrance and high degree of microsatellite instability (MSI-H) 
(Hsieh P., 2008). The CRC incidence is similar in subjects with 
mutations in MLH1 and MSH2 (84% and 71% respectively); 
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however, individuals with alterations in the MSH2 gene show a higher 
incidence (48-61%) of extracolonic malignancy (endometrial, gastric, 
ovarian and kidney cancer) than those carrying mutations in the 
MLH1 gene (11-42%) (Koornstra J.,2009). 
The clinical phenotype is different when minor genes are involved. 
Mutations in MSH6, for example, seem to cause a form of 
"attenuated" HNPCC, characterized by lower penetrance, later age of 
onset, usually around 60 years of age and low microsatellite instability 
(MSI-L) (Lucci-Cordisco E., 2001). 
Defects in the PMS2 gene are instead associated with early tumor 
development and microsatellite instability, although some features are 
different with respect to cancers caused by MLH1 and MSH2 
mutations. PMS2 mutations are associated with combined presence of 
multiple colorectal adenomas and glioblastomas (Turcot syndrome) 
(Van Meir EG., 1998). The specificity of brain tumor is probably 
linked to the accumulation of mutations in target genes (oncogenes, 
tumor suppressor) more specifically expressed in the brain (Chao E., 
2006). However, the need of multiple mutational events in distinct 
tissues (colon, brain) would explain the low penetrance and the rarity 
of this syndrome. 
In the MSH3 gene, missense, silent and intronic variations have been 
mainly identified; these mutations are associated with a severe 
phenotype in the case they are inherited in combination with each 
other, or associated with variants in the MSH2 gene (Duraturo F., 
2011). In fact, MSH3 knockout mice showed a low susceptibility to 
cancer development that caused late-onset colorectal cancer, whereas 
double mutant MSH3-MSH6 mice showed a very similar  phenotype 
to that found in mice lacking MSH2 (Kuraguchi M., 2001). These 
results are justified by the redundant function of the the MSH3 and 
MSH6 genes (Huang J et al., 2001). Moreover, MSH3 inactivation is 
primarily associated to instability of tetranucleotide repeats (EMAST) 
that has been frequently observed in moderately or poorly 
differentiated adenocarcinomas as well as in other cancers including 
lung, kidney, ovarian and bladder cancer (Haugen., 2008; Lee SY., 
2010). 
Similarly, mutations in the MLH3 gene are associated with a delayed 
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onset of disease but also with a more severe phenotype (MSI-H) in the 
case of co-existing MSH6 mutations (Liu H.-X., 2003). 
In recent years, numerous studies have found an association between 
the development of hematopoietic and intestinal tumors in infant age 
and the presence of homozygous mutations in the MLH1, MSH2, 
MSH6 and PMS2 genes (Bandippallian P.,2005; Herkert JC., 2011). 
This phenotype was also associated with heterozygous mutations in 
two or more MMR genes, suggesting a mechanism of compound 
heterozygosity (Plon SE., 2011; Poley JW., 2007; Peters A., 2009). 
In a subset of LS patients, a germline mutation at the 3’ end of the 
EPCAM (TACSTD1) gene has been identified resulting in allelic-
specific methylation and transcription silencing of MSH2, which is 
located upstream of the EPCAM gene. EPCAM gene encodes the 
Epithelial Cell Adhesion Molecule protein that is involved in cell 
signalling, migration, proliferation, and differentiation. Accordingly, 
this mutation may contribute to the development of extracolonic 
cancers (Kang SY., 2014). 
 
Non-canonical features: 
Recently a group of Lynch-like syndrome patients was described 
(Buchann DD., 2014; Lynch HT., 2014). This group may account for 
as much as 70% of suspected Lynch syndrome subjects. Unlike 
sporadic MSI cancer, Lynch-like patients are nearly impossible to 
differentiate from Lynch patients: they are MSI-positive and cancer 
tissues express abnormal MMR protein, not only for MLH1 as in 
sporadic MSI cancers but also for the other MMR proteins, such as 
MSH2, MSH6 and PMS2, as in true Lynch syndrome cancers. Lynch-
like patients show a mean age of onset comparable to LS. The only 
differentiating features between these two syndromes are the lower 
standardized incidence ratios for CRC and for non-CRC LS associated 
cancers in Lynch-like syndrome compared with the Lynch syndrome, 
and the absence of an identifiable DNA MMR gene germline mutation 
in Lynch-like syndrome. There are likely three potential reasons for 
cancer onset in Lynch-like patients: (a) a genetic process within the 
tumors other than germline mutations coupled with second allele 
inactivation, (b) unknown germline mutations in other genes than the 
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DNA MMR genes that can drive MSI, and/or (c) unidentified 
germline mutations in the DNA MMR genes (Carethers JM., 2014; 
Boland R., 2013). 
Mensenkamp AR et al. (Gastroenterology, 2014) noted that a 
considerable number of MSI-positive tumors lack any known 
molecular mechanism for their development. Patients were screened 
for somatic mutations and for loss of heterozygosity in MLH1 and 
MSH2 genes. This research identified two somatic mutations in 13 of 
25 tumors, 8 of which were MLH1-deficient and 5 were MSH2-
deficient, indicating that such acquired mutations underlie more than 
50% of the MMR-deficient tumors that have not been found 
associated with germline mutations or promoter methylation. This is 
in contrast with LS that is associated to germline mutations in the 
MMR genes.  
Moreover, other hereditary factors might play a role in tumor 
development. For example, deletions affecting genes that regulate 
MSH2 degradation were shown to lead to MMR deficiency and 
undetectable levels of MSH2 protein (Diouf B., 2011). Moreover, cells 
lacking SETD2 (H3K36 trimethyltransferase SET domain containing 
protein 2) display MSI due to the loss of an epigenetic histone mark 
that is essential for the recruitment of the MSH2-MSH6 complex. 
Whether these mechanisms lead to MSH2-deficient colorectal cancer 
remains to be shown (Li F., 2013). 
In these cases high-throughput sequencing procedures play an 
important role to identify new constitutive and somatic mutations in 
putative genes associated with hereditary predisposition to cancer 
(Zhang J., 2011, Duraturo F., 2013). 
It is also noteworthy that, in addition to canonical inactivation via 
gene mutation, MMR activity can also be modulated by changes in 
MMR gene expression. This type of alteration may be the result of 
mutations occurring in regions that are not always routinely analyzed 
such as the promoter and the 5’and 3’-untraslated regions. 
Previous studies have defined and characterized the core promoter 
regions of hMSH2 (from -300 to -17 upstream of the start codon) 
(Iwahashi Y., 1998) and hMLH1 (from -220 to -39 upstream of the 
start codon) (Ito E., 1999); subsequent studies have been carried out to 
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demonstrate that germline mutations in these regions are involved in 
HNPCC (Mrkonjic M.; 2007 Raptis S., 2007). 
Regarding mutations in the 3’UTR of MMR genes, a 3-nucleotide 
(TTC) deletion in the MLH1 3’UTR was found in leukemia patients 
(Mao G., 2008). This alteration was shown to destroy a binding site 
for miR-422a and, as a result, there is a down-regulation suggesting a 
possible role for the miRNA in regulation of MLH1expression (Mao 
G., 2012).  
Therefore, cell levels of MMR are likely to be subject to tight 
regulation in order to prevent that the overproduced protein may 
sequester other factors involved in controlling the mutation rate. 
Potentially adverse consequences of overproduced MLH1 and MSH2 
are highlighted by a report showing that apoptosis is induced in a 
human cell line when these two genes were expressed under the 
control of the cytomegalovirus (CMV) promoter. One possible 
explanation is the capture by MLH1 and MSH2 of proteins was 
crucial for cell cycle progression such as PCNA, a Proliferating Cell 
Nuclear Antigen protein, involved in DNA synthesis (Zhang G., 
1999).  
The dangerous excess of MMR protein can also be the effect of 
homodimerization complex as shown by a study in yeast cells of 
Shcherbakova et al. (Mol. Cell. Biol., 2001) showing that the MLH1-
MLH1 homodimer replaced the MLH1-PMS1/PMS2/MLH3 
heterodimer, inactivating also the MutSα and MutSβ functions, thus 
resulting in nonfunctional MMR complex. 
This concept is also partially extended to other minor MMR genes: 
overexpression of MSH3 gene in cultured mammalian cells 
selectively inactivates MutSα because MSH2 is sequestered into a 
MSH2-MSH3 (MutSβ) complex, resulting in reduced MutSα-
dependent repair of base-base mismatches and a strong base 
substitution mutator phenotype (Marra G., 1998). 
Finally, several MSI tumors with unknown cause of MMR 
inactivation could display a miRNA down- or up-expression 
genotype, that specifically modulate MMR genes (Landau DA., 2011, 
Dong Y., 2014). miRNA expression are in turn regulated by DNA 
damage (Wang Y., 2013). miRNAs able to regulate the mismatch 
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repair function are miR-155 and miR-21, that significantly down-
regulate the core MMR proteins, MSH2, MSH6 and MLH1, and have 
been associated with a mutator phenotype, in particular with MSI 
inflammatory bowel diseases (IBD) CRCs (Valeri N.,2010; Svrcek 
M.,2013).  
 
1.5 Characterization of the "variants of uncertain significance" 
(VUS) in the MMR genes 
Regardless of the site where a mutation occurs, the type of mutation 
also can make difficult a genotype-phenotype association.  
Several mutations identified in the MMR genes are missense, silent or 
intronic variants. The influence of these variants on the development 
of cancer is often a controversial topic, therefore they are classified as 
"VUS," Variant of Uncertain Significance (Syngal S., 1999; Couch 
FJ., 2008). 
Several criteria can be applied to assess the possible pathogenicity of a 
VUS, (Goldgar DE, 2008; Plon SE., 2008); these criteria are listed 
below: 1) de novo appearance; 2) segregation with the disease; 3) 
absence in normal individuals; 4) change of amino acid polarity or 
size; 5) occurrence of the amino acid change in a domain that is 
evolutionary conserved between species and/or shared between 
proteins belonging to the same protein family (in silico analysis); 6) 
effects on splicing or on protein function; 7) loss of the non-mutated 
allele due to a large deletion in the tumor DNA (loss-of-
heterozygosity [LOH]); 8) loss of protein expression in the tumor; 9) 
evaluation of MSI in tumor tissue. All studies conducted to date show 
that none of the above criteria, including functional assays, is an 
indicator of pathogenicity, if taken alone; it is necessary that a 
combination of strategies be used in combination in order to lead to a 
correct assessment of the pathogenicity of uncertain variants. 
According to these observations, a classification of MMR sequence 
variants identified by genetic testing has been proposed based on a 5-
class system, using a multifactorial likelihood model (Table 5). 
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Table 5. Proposed classification system for MMR variant interpretation (Colon 
cancer Family Registry 2009, InSiGHT Variant Interpretatioin Committee 2011). 
 
Variant-Class 5 includes coding sequence variation resulting in a stop 
codon (nonsense or frameshift), splicing aberration variants by mRNA 
assay, large genomic deletions or duplications, abrogated 
mRNA/protein function variants based either on laboratory assays, on 
evidence for co-segregation with disease and on MSI tumor and/or 
loss of MMR protein expression. 
Variant-Class 4 includes IVS+-1 or IVS+-2 mutations resulting in 
splicing aberrations, variants abrogating mRNA/protein function 
based on laboratory assays, evidence of co-segregation with disease or 
MSI tumor and/or loss of MMR protein expression. 
Variant-Class 3 includes large genomic duplications, missense 
alterations, small in-frame insertions/deletions, silent variants, intronic 
variants, promoter and regulatory region variants for which 
insufficient molecular evidence are available, and with intermediate 
clinical effects or low penetrance alleles. 
Variant-Class 2 includes synonymous substitutions and intronic 
variants with no associated mRNA aberration, with a proficient 
protein expression/function, lack of co-segregation and/or MSS tumor. 
Variant-Class 1 includes variants reported in control reference groups 
and excluded as founder pathogenic sequence variant.  
According to this classification, most of the VUS tested for the MMR 
genes are likely to be pathogenetic and thus they can be associated 
with the HNPCC phenotype. 
For the MLH1 gene, 52 out of 73 VUS are resulted to be pathogenetic 
(70%), similar pathogenicity has been demonstrated for 25 out of 35 
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VUS identified in the MSH2 gene, (71%) (www.insight- group.org). 
For minor MMR genes, percentage of pathogenic VUSs is reduced 
due to the milder mutational contribution of these genes to the 
development of the disease. For the MSH6 gene, only 1 out of 8 
variants studied (13%) was found to have aberrant effects on protein 
function; for the PMS2 gene, 4 variants were analysed and all (100%) 
seem to have a causative role in Lynch syndrome; for the MLH3 gene, 
however, functional assays have not identified any variant with certain 
pathogenetic significance; finally, for the MSH3 gene relevant 
functional studies have still not been reported (www.insight-
group.org). 
 
1.6 Probability of a "synergistic effect" between low risk allelic 
variants in the MMR genes 
With the advent of high-throughput technologies it has been possible 
to analyze a great number of polymorphic variants in large cohorts of 
cases and controls of specific cancers, such as breast, prostate and 
colorectal cancer, providing new insights into common mechanisms of 
carcinogenesis. In some cases, VUSs make a more substantial overall 
contribution to cancer risk than the well-assessed severe mendelian 
variants. It is also possible that the simultaneous presence of some 
polymorphisms and VUSs in cancer predisposition genes that behave 
as low-risk alleles, might contribute in a cooperative manner to 
increase the risk of hereditary cancer (Duraturo F., 2013). Therefore, 
current literature data suggest that a significant proportion of the 
inherited susceptibility to relatively common human diseases may be 
due to the addition of the effects of a series of low frequency variants 
of different genes, probably acting in a dominant and independent 
manner, with each of them conferring a moderate but even detectable 
increase in the relative cancer-risk. Therefore, several functional 
studies based on GWAS data related to cancer susceptibility have 
been performed in an attempt to demonstrate the effective association 
and to test the hypothesis of synergistic effects between low risk 
allelic variants. 
In a recent study on yeast genome, it has been shown that the minor 
alleles of the MMR complex cause a weak mutator phenotype; 
19 
Introduction 
however, their interaction causes a more severe mutator phenotype 
(Martinez SL., 2010). In this study, 11 polymorphisms and 14 
missense variants of uncertain significance previously identified in the 
MSH2, MLH1, MSH6 and PMS2 genes, were studied by 
complementation tests. The mutator effect of these variants was tested 
singly and in combination with each other. 
In 2011, Kumar et al. showed that some variants occuring in domain I 
of the MSH2 gene in yeast strains (msh2Δ1) behave as weak alleles in 
the presence of a functional protein MSH6, as they do not alter the 
stability of the MutSα complex. However, by combining these 
variants with weak alleles falling in the N-terminal region (NTR) 
(DNA binding domain) of the MSH6 gene, a strong mutator 
phenotype was found. Moreover, the mutator synergistic effect is also 
found  between different systems of DNA damage response. A recent 
population study by Smith et al. (2011) has shown that the 
simultaneous presence of mutations in the TP53 gene and single 
nucleotide polymorphisms (SNPs) in genes belonging to different 
repair systems as BER, NER, MMR and DSBR (Double-Strand Break 
Repair) complex, is associated with an earlier age of onset of breast 
cancer (<50 years). Therefore, in this case the authors suggest an 
additive or multiplicative effect. 
The additive effect of low penetrance genes could also be the cause of 
atypical Lynch syndromes such as familial CRC type X (Lindor NM., 
2005). With respect to LS, the familial CRC type X are more often 
located in the distal colon, extracolonic cancers are less frequent than 
in LS, and the age of onset is delayed. The sine qua non condition for 
this diagnosis is the absence of molecular genetic evidence of LS 
(MSI, IHC, or MMR mutations). 
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1.7 Scientific hypothesis and aim of the work 
Molecular characterization of patients with a clinical diagnosis of 
Lynch Syndrome currently relies on the identification of point 
mutations and large rearrangements by DHPLC and MLPA, 
respectively, in the major MMR genes, MLH1 and MSH2.  
This strategy does not always provide informative results for genetic 
counseling. Indeed, we analyzed 117 families selected according to 
international diagnostic criteria (Amsterdam Criteria and Bethesda 
Guidelines). Our study led to the identification of the molecular defect 
in 53 families while no MLH1/MSH2 mutations were identified in the 
remaining 64 families. Moreover, in several patients we were able to 
identify genetic variants of uncertain significance (VUS) (missense, 
intronic and silent variants).  
This thesis has been focused on the characterization of the VUS 
identified in the major MMR genes. This has been achieved using a 
combination of the following approaches: segregation analysis, 
population studies (to exclude the polymorphic nature of the variant), 
assessment of Microsatellite Instability (MSI) in tumor tissues, 
detection of loss of protein expression in tumor tissues by 
immunohistochemical analysis (IHC), in silico analysis by a variety of 
bioinformatics tools such as HSF (Human splicing Finder), PolyPhen 
(Polymorphism Phenotiping), SIFT (Sorting Intolerant From 
Tolerant), and PredictProtein, direct analysis on the mRNA by Real-
Time PCR to study gene expression modification and/or quantitative 
protein analysis by western-blot.  
According to literature data, our study has been based on a 
combination of different approaches in order to verify the 
pathogenicity of these uncertain variants. 
Analysis of two mutations detected in the 3’untranslated regions 
(3'UTR) of MLH1 and MSH2 genes have led to very interesting 
results. On the basis of in silico analysis, we had hypothesized that 
mutations in this regions may impair binding of putative 
transcriptional factors or microRNA involved in regulation of gene 
expression. By gene expression studies we have been able to 
demonstrate the pathogenetic significance of these variants.  
In this study we have also analyzed the minor MMR genes, MSH6, 
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PMS2, MLH3, and MSH3, for germline variants detected in patients 
negative for germline mutations in the major MMR genes. Recently, 
literature data indicated that MMR proteins have other functions 
besides the post-replicative repair, that could be highly relevant in 
carcinogenesis (cell cycle and apoptosis regulations, Jiricny J. 2006, 
Ji G., 2012, Mao G., 2012) and could involve the minor MMR genes, 
as well. Therefore, we speculated that genetic variants in these genes 
could have an important role in carcinogenesis progression. Several 
VUS were also identified in minor MMR genes. and phenotypic 
characterization was carried out for some of these variants. 
Finally, since many of the subjects analyzed showed co-inheritance of 
different genetic alterations in the MMR genes, we assume a likey 
additive role of low penetrance alleles in the disease development, in 
favor of a putative polygenic inheritance for Lynch syndrome, in 
according to recent literature data (Martinez SL., 2010). 
In conclusion, the aim of this study was to clarify the pathogenetic 
significance of many genetic variants identified in MMR genes. This 
will allow to clarify the genotype-phenotype correlations in these 
patients, in order to improve the genetic counselling and, 
consequently, the clinical surveillance.  
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2. MATERIALS AND METHODS  
 
2.1 Patients 
Sixty-four families of Italian origin of which 40 families classified 
according to the Amsterdam Criteria and 24 atypical Lynch families 
selected according to MSI (Bethesda Guidelines), without well-
defined pathogenetic germ-line point mutations or large 
rearrangements in the major MMR genes, MLH1, MSH2, were 
recruited from several Clinical Centers in Campania (Southern Italy). 
Samples from all families participating to the study were collected 
after informed consent of the participants. 
 
2.2 DNA, RNA and protein isolation 
Total genomic DNA was extracted from 4-mL peripheral blood 
lymphocytes collected with EDTA using a BACC2 Nucleon Kit 
(Amersham Life Science), according to the manufacturer’s 
recommendations, and from formalin fixed and paraffin embedded 
(FFPE) tumor/normal tissues by standard method. For FFPE 
extraction, tissue sections of 25 μm were previously cut with a 
microtome and then used. Each section (usually 4 for specimen) was 
dewaxed in 1 mL of xylene, then dipped in 1 mL of lysis solution 
containing 0.1 M Tris-HCl, 0.01 M EDTA, 1 M NaCl, 1% SDS, 400 
μg / mL of Proteinase K overnight at 48°C. DNA was extracted with a 
phenol/chloroform/isoamyl alcohol solution (25: 24: 1, v/v), 
subsequently with a chloroform/isoamyl alcohol solution (24: 1, v/v), 
and, finally, DNA was precipitated with two volumes of absolute 
ethanol and 1/3 volume of 3M sodium acetate, pH 5.5. After 
incubation overnight at -20°C, the pellet was washed with ethanol at 
70% and resuspended in sterilized TE buffer (Tris 10mM pH7.5-
EDTA 1mM pH8). 
Total genomic RNA was extracted from 4 mL peripheral blood 
lymphocytes collected with EDTA with TRIZOL solution (Qiagen) 
according to the manufacturer’s protocols. 
After extraction, both DNA and RNA were quantified by 
spectrophotometer analysis and their integrity was verified by 
electrophoretic analysis on 1% agarose gel. 
Total protein extracts were obtained from the same blood sample used 
for RNA isolation according to the Qiagen protocol. 
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Evaluation of protein concentration was performed by 
spectrophotometer analysis (λ = 595nm), according to the Bradford 
method using the Bio-Rad Protein Assay Reagent (Bio-Rad 
Laboratories). 
 
2.3 Microsatellite Instability (MSI) analysis 
The analysis of microsatellite instability was performed on DNA 
extracted from tumor and normal tissue/peripheral blood lymphocytes, 
with the GeneQuality CC-MSI kit (AB-Analytical). 
Through the use of oligonucleotides labeled with different 
fluorophores (HEX, FAM and TAMRA), 4 different amplified 
products with a single capillary electrophoresis running was 
performed, allowing simultaneous analysis of 12 microsatellite 
markers, since each mix allows amplification of 3 microsatellites, as 
shown in Table 6. 
 
Table 6. Microsatellites analysis with the GeneQuality CC-MSI kit (AB-
Analytical). 
  
The panel of amplified markers comprises five quasimonomorphic 
mononucleotide repeats, BAT-25, BAT-26, D2S123, D5S346, 
D17S250 (Bethesda Panel), four mononucleotide repeats, NR21, 
NR24, BAT40, and TGFβRII, one dinucleotide marker D18S58 and 
two tetranucleotide repeats, TPOX and TH01, with the latter two 
markers used as internal controls and not for evaluation of 
microsatellite instability. 
For each amplification, the reaction mixture is composed as fallows: 
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Buffer 10X (2.5 μL); MgCl2 (0.75 μL); dNTPs (0.5 μL); primer mix 
(1 μL); SuperABTaq (0.2 μL); H2O (up to volume); DNA (20-25 ng) 
in a final volume of 25 μL. The amplification program is the 
following: 95°C for 8 min, 10 cycles at 94°C (30 sec), 60°C →55°C 
(45 sec with 0.5°C/cycle decrement) and 72°C (30 sec), 22 cycles at 
94°C (30 sec), 55°C (45 sec) and 72°C (30 sec), and a final extension 
at 72°C (10 min). 
The electrophoretic separation by capillary electrophoresis on an ABI 
3130 Genetic Analyser (Applied Biosystems) is based on the 
molecular length of each fragment and on the fluorophore type, as 
shown in Table 10. Before electrophoresis, 1 μL of each amplicon was 
added to 24 μL of deionized formamide (Life Technologies) and 1 μL 
of size standard (GeneScan 500 ROX, Life Technologies), and 
incubated for 5 minutes at 95°C. After the electrophoretic run, normal 
and tumor multiplex-PCR electropherograms for each patient were 
compared by the GeneScan software (Applied Biosystems). 
 
2.4 Immunohistochemistry analysis 
Immunohistochemistry analysis was performed on an Benchmark XT 
automatized immunostainer (Ventana Medical Biosystems, Tucson, 
USA). The antibodies tested were: 
1) Anti-MLH1, mouse monoclonal clone M1 (Ventana); 
2) Anti-MSH2, mouse monoclonal clone G219-1129 (Ventana); 
3) Anti-MSH6, mouse monoclonal clone 44 (Ventana). 
The detection system used was a Ventana DAB-iView which is based 
on the Streptavidin- Biotin-conjugated revelation system. 
3-5 microns FFPE tumoral tissue sections were cut and let stick on 
electrostatically charged glass slides (SuperFrost) overnight at 42°C. 
Glass slides were loaded on an immunostainer Ventana BenchMark 
XT for automatic staining. Firstly the instrument operates a dewaxing 
and subsequently an incubation with the inhibitor of endogenous 
peroxidase (H2O2). The subsequent steps of antigen unmasking 
(HIER, Heat Induced Epitope Retrieval) and the antibody (Ab) 
incubation were setted as follows: 
 MLH1 MSH2 MSH6 
 
HIER 
90 min. at 99°C  
pH 8 
60 min. at 
99°C  
pH 8 
90 min. at 
99°C  
 pH 8 
 
Ab incubation 
40 min. at room 
temperature 
32 min. at 
37°C 
32 min. at 
37°C 
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Analysis was perfomed with the detection system “iView DAB” 
which consists firstly in dispensing the biotinylated secondary 
antibody and then the enzyme-conjugated streptavidin (HRP, 
horseradish peroxidase). The antigen positive complexes are detected 
by the addition of the DAB chromogen (diamminobenzodine) and its 
substrate (H2O2). The samples are finally counterstained with the 
nuclear dye hematoxylin. After immunostaining, slides are taken by 
the instrument, dehydrated, added with xylene and few drops of 
conditioner and mounted with a cover glass. 
Nuclear staining was observed with an optical microscope with 
positivity represented by the presence of brown staining. This 
positivity was compared to blue nuclear epitopes, in which the 
specific antigen was not present. The internal positive control was 
represented by lymphocytes, stroma and functional mucosal crypts, 
while the negative control was obtained by slides without primary 
antibody. 
 
2.5 MMR germline point mutations and large genomic 
rearrangements analysis 
For MMR (MLH1 GeneBank NG_007109.2, MSH2 GeneBank 
NG_007110.2, MSH6 GeneBank NG_007111.1, PMS2 GeneBank, 
NG_008466.1, MLH3 GeneBank NG_008649.1, and MSH3 
GeneBank NG_016607.1) germline point mutations analysis, DNA 
amplification reactions were performed with oligonucleotide primers 
chosen in order to include all exons and intron-exon boundaries of 
each gene. All oligonucleotides were obtained with PrimerBlast 
software (www.ncbi.nlm.nih.gov/tools/primer-blast/). PCR reactions 
were performed in a total volume of 50 μL containing 5 μL of 10X 
PCR buffer (Roche), 200 μM of each dNTP, 25 pM of each primer, 
1.5 mM of MgCl2, 2 U of FastStart Taq DNA polymerase (Roche) and 
100 ng of genomic DNA. PCR conditions were as follows: initial 
denaturation at 95°C for 4 min, followed by 35 cycles with 
denaturation at 95°C for 30 sec, annealing for 30 sec at the melting 
temperature of each primer, extension at 72°C for 45 sec, followed by 
a final extension step at 72°C for 7 min. The PCR products were 
analyzed on a 1-2% agarose gel in Tris-acetic acid (TAE)-EDTA 1X 
standard buffer and visualized by ethidium bromide staining.   
Identification of sequence variants within each amplicon was 
performed by DHPLC (Denaturing High Performance Liquid 
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Chromatography) analysis, using the Wave 3500HT system 
(Transgenomic), according to the manufacturer’s recommendations. 
Before dHPLC analysis, the PCR products were denatured at 95°C for 
5 min and gradually cooled to 20°C using a temperature ramp of 
1°C/min on a PCR thermocycler to enable efficient formation of 
heteroduplex. The mobile phase gradient and running column 
temperature selected for optimal heteroduplex separation were 
determined for each amplicon using the Wave Marker 4.4 software 
provided with the instrument. In cases of samples showing abnormal 
patterns on DHPLC, DNA sequencing in both the forward and reverse 
directions was performed using the ABI 3100-Avant automatic DNA 
sequencer (Applied Biosystems, CA). For nucleotide numbering, the 
first A of the initiator ATG codon is nucleotide +1 of the MMR 
mRNA sequence. 
Detection of large genomic deletions/duplications was performed by 
MLPA (Multiplex Ligation-dependent Probe Amplification) analysis. 
MLPA is a semi-quantitative multiplex PCR, performed using the 
SALSA MLPA P003-B1 MLH1/MSH2 kit (MRC-Holland) according 
to the manufacturer’s instructions. Fragment analysis was conducted 
on an ABI Prism 3130 Genetic Analyser using the GeneMapper 
sofware (Applied Biosystems). Migration of fragments was calculated 
by comparison to the GeneScan LIZ-500 size standard (Applied 
Biosystems). Peak areas were then exported to a Microsoft 
spreadsheet 
(www.mrc-holland.nd.) and calculations were done according to the 
method described by Taylor et al. (Human Mutation, 2003). A 30–
50% decrease in the peak area(s) indicated a deletion of the 
corresponding exon(s), while a 30–50% increase in the peak area(s) 
indicated a duplication of the corresponding exon(s). MLPA results 
were confirmed in at least two independent experiments and by cDNA 
sequencing. 
 
2.6 RNA based analysis 
For qualitative RNA analysis, MMR cDNA was synthesized using 1 
μg of total RNA, 500 μg of Oligo(dT)12-18, and 1 μL of Superscript III 
reverse transcriptase (Invitrogen), in the presence of 4 μL 5X RT 
buffer, 1 μL DDT (0.1 M) and 1mM dNTPs. The reaction was run for 
50 min at 42°C in a 20 μL of reaction volume, heated to 70°C for 15 
min and snap-chilled on ice. 
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1 μL of each cDNA was amplified with primers that produce several 
overlapping fragments covering all exons. The PCR reaction was 
performed as described above for DNA PCR. 
PCR products were analyzed on a 8%/10% polyacrylamide gel in 
Tris-Boric acid-EDTA (TBE) 1X standard buffer and visualized by 
silver staining. Bands of different lengths, corresponding to different 
splicing isoforms, were cut and eluted from gel in 30 μL of sterile 
water according to the procedure of the QIAquick Gel Extraction kit 
(Qiagen). Purified bands were amplified for sequencing analysis. 
Quantitative RNA analysis was performed by Real Time PCR on an 
CFX96 Real-Time System (Bio-Rad-Laboratories). PCR products 
were verified on agarose gel before performing the relative 
quantification. A calibration curve to assess the efficiency of the PCR 
reaction was performed on at least three serial dilutions (1:10) of the 
reverse transcriptase products. Each Real Time PCR (100-150 bp 
long) was performed in triplicate in a 20 µL reaction mix containing 
12.5 μL of 2X SYBR Green I PCR Master mix (Bio-Rad 
Laboratories), 0.38 μL of a 20 μM primer mix, 2 μL of cDNA (5ng/ 
μl) and 7.12 μL of nuclease-free water. The cycling conditions 
consisted of an initial denaturation step at 95°C for 3 min, followed by 
40 cycles (95°C for 15 sec, 62°C for 30 sec, 82 °C for 20 sec) and 80 
cycles performed according to standard protocols for melting curve 
analysis. CT values were determined by automated threshold analysis 
and data were analyzed with the CFX Manager software version 2.1 
(Bio-Rad Laboratories). The relative expression of the target transcript 
was calculated with the comparative Ct method using a cDNA 
fragment from the glucoronidase (GUS) housekeeping gene as 
control. Three several forward and reverse primers for MLH1 cDNA 
quantification were carried out, by amplifying fragments spanning 
between exons 3-5, 4-5 and 13-14. Two forward and reverse primers 
for MSH2 cDNA quantification were designed, by amplifying 
fragments spanning between exons 4-5 and 13-14 (Tab.7). 
 
2.7 Protein analysis 
Western blot analysis was performed on 30-50 µg of total protein 
extracts. Proteins were denatured at 95°C for 10 min in a buffer 
containing 2% (w/v) SDS, 10% (v/v) glycerol, 5% (v/v) β-
mercaptoethanol, 75 mM Tris/HCl pH 6.8, 0.001% (w/v)  
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Table 7. Primer sequences and amplicon size for MLH1 and MSH2 mRNA 
quantification. 
 
bromophenol blue and separated by SDS-page electrophoresis in a 
10% Acrylamide/Bis 29:1(v/v) gel (Tris/HCl 1.5 M pH 8.8, SDS 
10%) for 2 hours at 100 volts. Proteins were then transferred on a 
nitrocellulose membrane (GE Healthcare) in a Tris-Glycine-SDS (Tris 
25 mM, Glicine 192 mM, SDS 0.1% ) buffer.  
Proteins were visualized by reversible staining with a solution of 0.1% 
Red Ponceau S (Sigma-Aldrich) in 5% acetic acid solution. 
After elettroblotting, non specific sites on the nitrocellulose membrane 
were saturated over night at 4°C with a milk solution (5% w/v) 
containing 0,1% Tween 20 (w/v) in TBS 1% (Tris HCl 1mM pH 7.5, 
NaCl 15 mM). Filters were incubated over-night at 4°C with the 
following antibodies: mouse monoclonal anti-MSH2, clone GB12,  
(Calbiochem) diluted 1:100, and mouse monoclonal anti-MLH1, 
cloneG168-15 (BD Pharmingen) diluted 1:250 and subsequently 
normalized with a mouse antibody anti α-actin (dil 1:1000). 
Membranes were washed with 1x TBS-Tween 20 buffer for 5 minutes 
(3 times) and incubated for 45 minutes with a secondary antibody 
(anti-mouse dil 1:10000) conjugated to peroxidase (Sigma). The 
antigen-antibody complexes were visualized by the ECL-Immobilon 
chemiluminescence reagents (Millipore) and subsequent 
autoradiography. Western blots bands were quantified by the ImageJ 
software. 
 
2.8 In silico analysis 
In silico analysis was performed for all MMR gene variants of 
uncertain significance, not yet reported in literature, using the 
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following bioinformatics tools: 
 Human Splicing Finder (HSF) (www.umd.be/HSF/) for 
missense, silent and intron variants; 
 Phenotiping Polymorphism (PolyPhen)  
 (http://genetics.bwh.harvard.edu/pph/) for missense variants; 
 Sorting Intolerant From Tolerant (SIFT)  
 (http://blocks.fhcrc.org/sift/SIFT.html) for missense variants; 
 Predict Protein (https://www.predictprotein.org/) for missense 
variants. 
HSF software is a new tool used to predict the effects of mutations on 
splicing signals or to identify splicing motifs in human sequences. It 
contains all available matrices for auxiliary sequence prediction and 
also presents a new position weight matrix to assess the strength of 50 
and 30 splice sites and branch points. 
PolyPhen, SIFT, and PredictProtein algorithms were used to perform 
structural analysis of missense point mutations in order to evaluate the 
functional activity of the mutated protein. Predictions are based on a 
combination of phylogenetic, structural and sequence annotation 
information with the substitution position in the protein. The range-
scores calculated for each program are as follows: 
 
 
PolyPhen 
 
Benigne Δ≤ 0.5 
Probably 
damaging 
0.5< Δ ≤1.5 
Possibly 
damaging 
≥1.5 
SIFT Not affected >0.05 Affected <0.05 _ 
 
PredictProtein 
 
Neutral effect<-50 
<-50 score <50 
weak effect 
>50 
strong 
effect 
 
In silico analysis was also performed to identify regulating factors of 
gene expression and their target motifs, in gene sequences such as 
promoter and untranslated regions. The following bioinformatics tools 
were used: 
 TRANSFAC(http://www.biobaseinternational.com/product/tra
nscription-factor-binding-sites) to search DNA sequences for 
putative transcription factor binding sites; 
 TargetScan 6.2 (http://www.targetscan.org), miRanda 
(http://www.microrna.org), miRDB (http://mirdb.org) that 
predict biological targets of miRNAs by searching for the 
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presence of conserved 8mer and 7mer sites that match the seed 
region of each miRNA. 
 
2.9 Functional analysis 
The MSH2 3’UTR variant (c.*226 A>G) identified at the 
heterozygous state in a HNPCC family was tested by the Luciferase 
Reporter assay. 
The MSH2 3’UTR of a carrier of this mutation was amplified by PCR 
with a primer pair containing XhoI and NotI restriction sites, 
respectively. Oligonucleotide sequences were as follows: 
 
XhoI-3’UTR MSH2 
farward 
ATACTCGAGAAAATCCCAGTAATGGAATG 
NotI-3’UTR MSH2 
reverse 
ATAGCGGCCGCTTCAAATTCCACAAACTACA 
 
The adapter bases are indicated in red, while the restriction sites are 
indicated in blue. The whole amplicon sequence (296bp) was tested 
for restriction enzyme sites by the GeneJockey II software. 
PCR reaction was performed as above described (paragraph 2.5) at a 
melting temperature of 60°C. 
The PCR product was cloned into the PSICHECK2 vector (Promega) 
(Fig. 4), downstream from the Renilla luciferase  coding region 
(hRluc). 
The wild-type and the mutated constructs were transfected in SW480 
cells (MMR+ human colon adenocarcinoma), using Lipofectamine 
2000 (Invitrogene) as transfectant agent. These cell lines grow as 
adherent cells in RPMI 1640 (Gibco) supplemented with 10% fetal 
bovine serum (Sigma), 1% GlutaMAX-I (Invitrogen) and 1% 
Penicillin/Streptomycin (Gibco). The cultures were maintained at 
37°C in a 5% CO2-humidified atmosphere and they were kept sub-
confluent (70-80%) for the subsequent transfection experiments. 
24 hours before transfection adherent cells were plated into 96-well 
plates at a density of 25 x 103 (70-90% confluence) in 100 µL of 
Optimem Medium (Invitrogen) in the absence of serum/antibiotic. 
Subsequently, two solutions were prepared, containing 30ng/µL of 
plasmid diluited in Opti-MEM medium (24µL) and 0,5 μL of 
Lipofectamine diluited in Opti-MEM medium (24,5 μL), respectively. 
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Figure 4. Graphic representation of  the PSICHECK2 vector. 
 
These two solutions were mixed in a single tube, and incubated 20 
minutes at room temperature. This mixture was added to each well 
(50µL). The plate was incubated at 37°C. Subsequently, 50/100 μL of 
OptiMEM was added to each well. The plates were incubated for six 
hours in the appropriate growth conditions (37 ° C, 5% CO2) and then 
10% FBS was added in each well. Luciferase activity was measured at 
48 h after transfection, using a dual luciferase reporter assay 
(Promega) according to manufacturer’s instructions and performed on 
a 20n/20n Luminometer (Turner BioSystems). Relative luciferase 
activity was calculated by normalizing the Renilla luminescence to the 
firefly luminescence. The assay was performed in 5X replication in 
three independent experiments. 
Then, HT29 (MMR+ human colon adenocarcinoma) and SW480 cells 
were transfected with the pre-miR miRNA precursor hsa-miR-137 
(Ambion, Life Technologies) and pre-miR miRNA negative control 
FAM (Ambion, Life Technologies) at a final concentration of 30 nM, 
using Lipofectamine 2000 (Invitrogen) according to manufacturer’s 
instructions. For qRT-PCR analysis, total RNA was extracted 48h 
after transfection, with TRIZOL solution (Qiagen) according to the 
manufacturer’s protocols. 
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3. RESULTS 
 
In this study, we analyzed the DNA samples of 64 subjects, belonging 
to families diagnosed with Lynch syndrome, in which no germline 
point mutations or large rearrangements in MMR genes, hMLH1 and 
hMSH2, had been found. Variants of uncertain significance (VUS) 
were identified in these major MMR genes. 
The 64 families were selected on the basis of the Amsterdam criteria 
and Bethesda guidelines, as follows: 
 40 families fulfilling the Amsterdam Criteria; 
 24 families identified according to the Bethesda Guidelines 
and classified as "HNPCC", on the basis of the presence of 
high/low microsatellite instability (MSI-H/L) and the absence 
of  the BRAF mutation. 
In these families several VUS were identified in the major MMR 
genes and extensive phenotypic characterization was carried out on 
some of them in order to investigate their potential pathogenic role; 
furthermore, samples negatives for pathogenic variants in major MMR 
genes were then analyzed for mutations in the minor MMR genes, 
MSH6, PMS2, MLH3 and MSH3. 
 
3.1 Phenotypic and functional characterization of VUS in the 
major MMR genes  
In the MLH1 gene, we performed a phenotypic and a functional 
characterization of 3 of the most interesting variants of uncertain 
significance that had been identified and associated with severe 
disease phenotypes (Table 8). 
The missense mutation in exon 3, c.304G>A (p.Glu102Lys) (Fig.5), 
was found in a subject, belonging to an Amsterdam Criteria family, t 
had developed a tubule-villous adenocarcinoma of the colon at the age 
of 44 years (MSI-H).  
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Table 8. VUS identified in the MLH1 gene  in patients with MSI-H. 
 
 
Figure 5. Identification of the c.304G>A mutation in the MLH1 gene. (A) DHPLC 
analysis and (B) DNA sequencing analysis of exon 3.  
 
This variant had been previously reported as a class-3 variant of 
uncertain significance. In our case, it was not possible to carry out a 
segregation study for this variant, due to the limited availability of 
family members. 
Nevertheless, we were able to use alternative approaches to ascertain 
its pathogenic significance, according to the multifactorial likelihood 
model (Goldgar DE., 2008; Plon SE., 2008). 
First, this variant was not identified in 52 healthy controls, thus 
allowing us to exclude it as a polymorphic site. Secondly, according to 
the fact that this variant falls in an evolutionarily conserved region, 
functional prediction by PolyPhen, SIFT and PredictProtein 
algorithms indicated that this sequence variant may affect the protein 
function (Fig. 6). Finally, the HSF analysis revealed the loss of a 
binding site for SF2/ASF (enhancer splicing factor) (Fig. 6, 7), thus 
reinforcing that this alteration could be responsible for a defect in the 
normal splicing process.  
To verify this hypothesis, we extracted RNA from lymphocytes of the 
patient and of three normal controls. Using primers that amplify a 
cDNA region of MLH1 spanning exons 2-4 (forward primer: 5’-
A B 
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TGTTAAAGAGGGAGGCCTGA-3’) (reverse primer: 5’-
TCCATCAGCTGTTTTCGTTG-3’), we obtained a PCR product of 
216 bp, corresponding to the normal allele in all samples. 
  
Figure 6. In silico analysis of the c.304G>A mutation identified in the MLH1 gene. 
1A new criptic splice site (5ss’) created by the mutation (∆CV: coefficient of variation). 
The scores reported for each analysis were according to the score-range calculated 
by the algorithms (see section 2.7 of Material and Methods).  
 
In addition to the fragment of the expected molecular weight, in the 
patient’s sample we found a weaker fragment of slightly lower 
molecular weight, probably corresponding to an abnormally spliced 
allele (Fig.7). 
Sequence analysis of this abnormal fragment, after elution from the 
gel and re-amplification, revealed the presence of a 5 bp deletion, due 
to the activation of a cryptic splice site (Fig. 8). Therefore, the 
missense p.Glu102Lys variant acts as a truncating variant since it 
generates a down-stream premature stop codon at codon 120 and, 
consequently, a loss of function at the protein level.  
We also analyzed another MLH1VUS variant, the c.438A>G in exon 
5 (Fig.9).  
It is a silent variant (p=Gln146) identified in a patient who had 
developed colon cancer when about 50-year aged, and who belonged 
to a family in which several cases of abdominal tumors had been 
observed. Unfortunately, it was impossible to analyze other members 
of the family, but we ruled out the presence of the alteration in the 
DNA of 60 healthy subjects. Furthermore, even for this variant we 
performed an in silico analysis to predict its pathogenicity. The 
computational analysis performed using the HSF program indicated 
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that this nucleotide change resulted in the creation of a new binding 
site for SF2/ASF that could adversely affects the splicing mechanism 
(Fig. 10). 
To verify this hypothesis, we extracted RNA from lymphocytes of the 
patient and of three normal controls. We amplified a region 
encompassing the entire MLH1 transcript using a forward primer (5’-
ACGTTTCCTTGGCTCTTCTG-3’) and a reverse primer  (5’-
AATCAATCCACTGTGTATAAACCAA-3’) and in all samples we 
obtained a PCR product of the expected normal size (2,464 bp). In 
addition to this main band, we also observed the presence of several 
fragments of lower molecular weight (Fig. 11). These fragments were 
present in all samples, although in the patient’s sample these abnormal  
 
 
 
Figure 7. Analysis of MLH1 cDNA in a patient carrier of the c.304G>A variant.  
10% polyacrilamide gel electrophoresis of the MLH1 cDNA ex2-4 fragment of the 
patient (pz) and of a normal control (ctr); the arrows show the normal fragment (up) 
and a weak abnormal fragment of slightly lower molecular weight (down); M: size 
marker IX (Roche).  
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Figure 8. HSF-ESEFINDER analysis of the MLH1 c.304G>A mutation (left) and 
sequencing analysis (right) of the MLH1 cDNA ex2-4 abnormal fragment. 
 
 
Figure 9. Identification of the c.438A>G mutation in the MLH1 gene. (A) DHPLC 
analysis and (B) DNA sequencing analysis of exon 5.  
 
 
  
Figure 10. HSF-ESEFINDER analysis for the MLH1 c.438A>G mutation. 
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fragments were much more represented to the full-length mRNA. 
Sequence analysis of these fragments allowed us to characterize all of 
them as products of alternative splicing of the MLH1 gene; we 
observed mRNA isoforms with the in-frame skipping of exons 17-18, 
exons 6/9/10, exon 15, exon 9/10 and exons 9/10/11, respectively.  
 
Figure 11. Polyacrylamide electrophoresis analysis of the MLH1 cDNA in a patient 
carrier of the variant c.438 A>G and in three normal controls samples; the arrow 
shows the amplified fragment corresponding to the full-lenght cMLH1; the bands 
below correspond to alternative splicing isoforms. Marker XIV (Roche). 
 
To confirm this data, we set up a quantitative real-time PCR reaction 
in which fragments corresponding to exons 3-5, 4-5 and 13-14 of the 
MLH1 transcript were amplified, using GUS as a reference gene. 
Fragments encompassing the region in which the variant falls (3-5 and 
4-5 exons fragments) were under-represented in the patient with 
respect to normal controls whereas expression of the 13-14 fragment 
showed no significant differences between patient and controls (Fig. 
12). These data indicate that the creation of a new binding site for the 
enhancer protein SF2/ASF could promote the process of alternative 
splicing, thus causing the formation of a greater number of aberrant 
isoforms. 
The other MLH1 variant analyzed was the c.*30_32delTTC (3’UTR), 
identified in several HNPCC families and not present in 54 healthy 
subjects (Fig.13). This variant was described in literature as a class-1 
variant of uncertain significance. However, in our study, this alteration 
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was always associated with a severe phenotype (MSI-H) when it was 
co-inherited with another variant, the c.454-51t>c, described in 
literature as class-1 (table 9). 
 
 
                                
Figure 12. q-Real-Time PCR analysis of MLH1 mRNA in the patient with the 
variant c.438A>G. Gray columns represent means ± SD of 3 different negative 
controls. The results represent the average of three independent experiments. 
 
 
Figure 13. Identification of the c.*30_32delTTC mutation in the MLH1 gene. 
(A) DHPLC analysis and (B) DNA sequencing analysis of the MLH1 3’UTR. 
 
The computational analysis performed by the HSF program for this 
intronic variant showed a possible deleterious effect on the splicing 
process (Fig.14). Therefore, we may assume for these two genetic 
alterations a pathogenic additive effect. 
We could not apply the several bioinformatic analysis to the variant 
c.*30_32delTTC since it occurs in an untranslated region, therefore 
we used the TRANSFAC algorithm for prediction of TF binding sites. 
The results showed that the variant destroys the binding site for one of 
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two TF identified by the program (fig. 15). Recently, a computational 
analysis has identified a putative binding site for miR-422a in the 
MLH1 3’UTR that is disrupted by the 3-nucleotide deletion. A 
reciprocal feedback regulation mechanism between MLH1 and miR-
422a was also demonstrated (Mao G., 2012). 
 
Table 9. Families with the c.*30_32delTTC and c.454-51t>c mutations in the 
MLH1 gene. Families (n.1 to n.5) with double mutation, c.*30_32delTTC and 
c.454-51t>c; family (n.6) with only the c.*30_32delTTC mutation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. HSF analysis of the c.454-51t>c variant. ESS motifs by Fas-ESS 
algorithm: Exonic Splicing Silencer; PESS motifs by PESS-octamers algorithm: 
Putative Exonic Splicing Silencers; IIEs motifs: Intron-Identity Elements. 
 
On the basis of these data, we examined the MLH1 expression at 
mRNA and protein levels in a patient carrier for this variant. Indeed, 
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quantitative real-time PCR showed a reduction in MLH1 mRNA 
levels in one of the patients with the mutation (Fig. 16). 
 
 
 
 
 
Figure 15. TRANSFAC analysis of the MLH1 3’UTR. (A) wild-type sequence and 
interaction between the region c.*30_32 and two factors, GR (glucocorticoid 
receptor) and SPIB (Tf acting in B-cell receptor signaling); (B) mutated sequence 
and interaction between the c.30_32delTTC region and SPIB. 
 
Western blot analysis of proteins isolated from the lymphocytes of 
patient carrier of this mutation revealed a lower level of MLH1 in the 
patient compared to a negative control (Fig. 17).  
 
A 
B 
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Figure 16. MLH1cDNA q- Real-Time PCR analysis in a patient with the two 
variants, c.*30_32delTTC and c.454-51t>c. Green columns correspond to results 
from the patient. Pink columns represent means ± SD of 3 different negative 
controls. The results were the average of three independent experiments. 
 
 
Figure 17. Western blot analysis of MLH1 expression in patient with two variants 
c.*30_32delTTC and c.454-51t>c. Actin was used as an internal (positive) control. 
 
These results were confirmed by immunohistochemical analysis (IHC) 
on tumoral tissue sections of a patient carrier of this mutation. We 
observed low intensity of the nuclear staining for assessment of 
MLH1-protein expression compared to MSH2 and MSH6 protein 
expression (Fig. 18). 
These results were in accordance with previous literature data (Mao et 
al. 2008) and are indicative of pathogenicity for this variant. 
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Figure 18. MLH1, MSH2, MSH6 immunohistochemistry (IHC) in a patient carrier 
of the c.*30_32delTTC and c.454-51t>c mutations. Low intensity MLH1 (1)10X 
and (2) 20X; strong intensity MSH2(3) 10X and (4) 20X; strong intensity MSH6 (5) 
10X and (6) 20X. Colon tumour cells (filled arrow head point) and IHC+ 
lymphocyte internal control (open arrow head point ). 
 
We performed a multivariate analysis for 1 out of 3 variants of 
uncertain significance detected in the MSH2 3’UTR, the variant 
c.*226A>G, that was found associated with severe phenotypes (Table 
10). 
This mutation was identified in three subjects of an HNPCC family 
and was not present in 54 healthy controls (Fig.19). It had been 
described in literature as class-2 of uncertain significance. 
In our study, this alteration was associated with low microsatellite 
instability (MSI-L) and with diversified phenotypes, as showed in the 
pedigree of the mutation carrier (Fig.20). 
A computational analysis was performed by the TRANSFAC program 
for prediction of TF binding sites, and a combination of three different 
software alghoritms (TargetScan 6.2, miRanda, miRDB ) that predict 
biological targets of miRNAs. Results are shown in figure 21 and 22, 
respectively.  
According to in silico analysis, we performed a quantitative real-time 
PCR analysis that showed increased levels of MSH2 mRNA 
expression in all the three patients with the mutation (Fig. 23). 
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Table 10. VUS identified in the MSH2 gene in patients with MSI-H and MSI-L. 
 
 
 
Figure 19. (A) DHPLC analysis and (B) DNA sequencing analysis of the MSH2 
3’UTR: identification of the c.*226A>G mutation. 
 
 
Figure 20. Pedigree with the segregation of the c.*226A>G mutation. The red arrow 
indicates the family index case. 
 
Western blot analysis of proteins isolated from lymphocytes of one 
(III-2 index-case) of the three patients showed an increased level of 
MSH2 in the patient compared to negative controls, in accordance 
with the real-time data (Fig. 24).  
A B A 
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An immunohistochemical analysis (IHC) of FFPE tumoral tissue 
sections of two patients (II-6 endometrial tissue and III-2 colon tissue) 
revealed an increased level of MSH2 protein compared to normal 
tissues (Fig. 25, Fig. 26). 
 
 
Figure 21. TRANSFAC analysis of the MSH2 3’UTR. (A) Wild-type sequence and 
interaction between the mutated region c.*226A>G and four protein factors, 
ZNF333 (zinc-finger protein 333), POU6F1 (Tf acting in B-cell receptor signaling), 
CDP (cut-like homeobox1 protein), and PMX1 (paired related homeobox 1 protein). 
(B) Mutated sequence and loss of interaction between the mutated region 
c.*226A>G and each of the four factors. Red arrows indicate the WT (A) and Mut 
(B) nucleotide. 
 
In order to determine whether the variant c.*226A>G in the MSH2 3-
UTR altered the expression of upstream coding sequences, the WT 
and MUT 3’-UTR were cloned downstream the Renilla luciferase 
reporter gene (Fig. 27).  
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The reporter gene constructs were transfected into SW480 cells and 48 
hours later cells were collected for luciferase assay and quantitative 
mRNA analysis. Results showed that the construct bearing the MUT 
3’-UTR consistently induced higher luciferase activity than the 
construct with the WT 3’UTR (Fig. 28). 
We next performed a functional study to determine whether in vitro 
miR-137 interacts with the MSH2 3’UTR, according to previous in 
silico analysis and to literature data that indicate this miRNA as a 
tumor suppressor in the colon, inhibiting cell proliferation. The effect 
of miR-137 on the MSH2 transcript was investigated in two colorectal 
cancer cell lines, HT29 and SW480, that express high and low levels 
of the miR-137, respectively (Balaguer F., 2010 ). 
All transfections were performed in triplicate in 12-well plates. As 
shown in Fig. 29, the ectopic miR-137 expression after 48h of 
transfection significantly down-regulated the MSH2 mRNA levels in 
both cell lines particularly in HT29 cells, suggesting a possible role 
for this miRNA in MSH2 expression regulation. 
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Figure 22. In silico analysis of the MSH2 3’UTR by the prediction tools TargetScan 
(up) and miRanda (down). The miRNA identified were hsa-miR-137 and has-miR-
4795-3p by TargetScan, and hsa-miR-137 by miRanda.  
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Figure 23. q-Real-Time PCR analysis of the MSH2 mRNA in the patients with the 
c.*226A>G variant. Yellow, green and rex columns represent the mRNA of II-6, III-
2 and III-4 pedigree cases, respectively. Beige columns represent means ± SD of 3 
different negative controls. The results represent the average of three independent 
experiments. 
  
 
Figure 24. Western blot analysis of MSH2 expression in the index-patient with the 
c.*226A>G variant. Actin was used as an internal positive control. 
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Figure 25. MSH2 immunohistochemistry (IHC) results in III-2 index patient. (1) 
Strong positive IHC (80% staining intensity) in the colon tumor cells (filled arrow 
heads point) 10X and (4) 20X; (2) strong positive IHC (80% staining intensity) in 
the normal mucosa cells (filled arrow head point) of the patient 10X and (5) 20X; 
(3) weak positive IHC (30% staining intensity) in normal mucosa colon cells (filled 
arrow head point) of a control subject 10X and (6) 20X.  
 
 
Figure 26. MSH2 immunohistochemistry (IHC) results in the II-6 patient. (1) 
Strong positive staining (100%) in the endometrial atrophic polyp cells (filled arrow 
head point) 10X and (2) 20X, compared with IHC+ internal stromal cells (80% 
staining intensity) (open arrow head point). 
 
Figure 27. Schematic diagram of the WT and Mut luciferase reporter gene 
constructs. 
49 
Results 
 
 
Figure 28. Relative Luciferase expression. The Renilla luciferase reporter activity is 
significantly increased in MUT-3’UTR vector compared to WT-3’UTR in SW480 
cells (p<0.005). The data were normalized to the Firefly luciferase activity. Values 
are expressed in percentage as the mean ±SD of three replicate experiments.  
 
 
 
 
Figure 29. q-Real-Time PCR analysis of endogenous MSH2 mRNA in the HT29 
and SW480 cells transfected with hsa-miR-137 and a negative control (FAM). 
Results represent the average of three independent experiments. 
 
3.2 Mutational analysis of minor MMR genes 
Screening for point mutations was performed by DHPLC and 
sequencing analysis on amplicons corresponding to the MSH6, PMS2, 
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MLH3 and MSH3 coding regions while large genomic 
deletions/duplications analysis was carried out by Multiplex Ligation-
dependent Probe Amplification (MLPA) as described in Materials and 
Methods.  
A total of 77 variants were identified in the minor MMR  genes, 5 of 
which were pathogenic mutations, 5 were missense variants already 
described in the literature as pathogenic mutations (Fig. 30) and 67 
resulted to be unclassified variants (missense, silent and intronic 
variants) (Fig.31). 
A multivariate analysis was performed for these 67 VUS, by 
phenotypic characterization (segregation study, analysis on 52 
negative control samples, MSI and IHC analysis) and functional 
studies (in silico analysis, mRNA and protein analysis).  
 
 
Figure 30. Pathogenic mutations identified in minor MMR genes. 
 
 
Figure 31. Histogram of several VUS identified in the minor MMR genes.  
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This approach allowed us to demonstrate the likely pathogenicity of 
10 out of 27 variants identified in the MSH6 gene, 3 out of 21 
variants identified in the PMS2 gene, 2 out of 15 variants identified in 
the MLH3 gene, and 2 out of 13 variants identified in the MSH3 gene 
(data not shown). 
The most relevant result of this mutational analysis on minor MMR 
genes was the detection of multiple co-inherited molecular alterations 
in different genes in a group of patients. Table 11 reports the subjects 
who resulted to be carrier of this condition, in relation to their clinical 
phenotype.  
Anyway, to evaluate the pathogenic role of these variants, it would be 
necessary to analyze the members of each family to verify the 
segregation of each of these mutations with the disease. 
Unfortunately, this study was possible only for one family of the 64 
subjects analyzed, because of the poor cooperation of the other 
families. The pedigree of this family is shown in Figure 32A. 
Mutational analysis of the MLH1 and MSH2 genes in the index case 
allowed us to identify the silent mutation c.984 C> T in exon 6 of the 
MSH2 gene. Analysis of the minor MMR genes identified the 
following mutations: the c.693 G> A in exon 4 and the c.2732 T> G in 
exon 20 of the MSH3 gene, and the c.408 T> C in exon 1 of the 
MLH3 gene. This analysis was extended to other nine family 
members. The results are reported in Figure 32B. Analysis of 
microsatellite instability was carried out on DNA extracted from 
tumor tissue and normal mucosa of subjects II-5 (proband) and III-3 
(proband’s affected child). This analysis showed a high degree of 
microsatellite instability (MSI-H) and this is in agreement with the 
strong mutator phenotype observed in the two patients (Fig. 33). 
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Table 11. Patients with more mutations in the MMR genes. 
 VARIANTS CLINICAL HISTORY FAMILY HISTORY 
06/1 PMS2:  ex2 c.59 G>A (Arg20Gln), 
ex12c.2007-7c>t, ex15 c.2570 G>C 
(Gly856Ala),                                                
MSH3: ex23 c.3131 
G>a(Ala1044Thr) +/+ 
Moderately differentiated 
mucinous adenocarcinoma at 
age 51; endometrial cancer 
at age 55. 
Mother dead of intestinal obstruction at age 
52; father dead of colon cancer at age 48; 
two brothers dead of colon cancer at age 42 
and 50, respectively. 
06/2 MLH3: ex4 c.3484 
A>T(Ser1161Cys),                            
MSH3: ex20 c.2732 T>G 
(Leu910Thr) 
Moderately differentiated 
endometrial carcinoma at 
age 63;  sigma-rectum 
mucinous adenocarcinoma at 
age 68. 
Mother dead of intestinal obstruction at age 
35; sister with uterus cancer at age 57; sister 
dead of intestinal obstruction at age 64; 
cases of leukemia, lymphoma and 
meningioma among children. 
06/3 MSH2: ex7c.1077-10T>C                                                                                                 
PMS2: ex7c.780 C>G(Ser) +/+,                                     
MLH3: ex11 c.4263G>a (p=Gln) +/+, 
ex4 c.3484 A>T(Ser1161Cys)                     
Left colon cancer at age 70 
with liver metastates. 
Parents dead of old age; brother with 
bladder cancer at age  50; brother with lung 
cancer at age 72; sister with  fibromatous 
uterus at age 49 and rectum polyp at age 59. 
06/4  MLH3: c.184_190delGGGAGTG 
(Gly61fs), ex4 c.3484 
A>T(Ser1161Cys) +/+,  
ex11c.4263G>a (p=Gln) +/+                                
Colon cancer at age 49; lung 
metastates at age 57. 
Grandfather dead of intestinal obstruction at 
age 63; father dead of colon cancer at age 
58; sister with kidney and uterus cancer at 
age  46; sister with sigma colon and uterus 
cancers at age 53;  daughter with polyp at 
age 30. 
01/3 MSH6: ex5 c.3261_62insC 
(Phe1087fs)                                                                        
MSH3: ex12 c.1860G>A (Asp>Asn), 
ex12 c.1763+71c>a         
Right  poorly differentiated 
adenocarcinoma at age 61. 
Mother with colon-rectum cancer at age 50; 
brother with colon-rectum cancer at age 58; 
sister with colon adenoma at age 63 but 
negative at molecular testing. 
01/5 MSH6: ex5 c.3295_97delTT 
(Ile1098fs),                                       
MLH3: ex1-3 c.666 G>A (Lys), ex1-9 
c.2221 G>T(Val740Phe)(2003), ex1-
11 c.2533A>G (Ser844Gly),   
ex3c.3465+37_40del tctt, 
ex10c.4170+13c>g(2003) 
Moderately differentiated 
adenocarcinoma at age 46; 
brother not affected and 
negative at molecular 
testing; sister with colon 
polyp at age 30 but negative  
at molecular testing. 
Grandmother with colon cancer at age 78;  
father with colon cancer at age 50; uncle 
with colon cancer at age 70; cousin with 
colon cancer at age 46; uncle with colon 
cancer at age 64 and his child with several 
cases of polyps and uterus cancer between 
35 and 50 years. 
04/15 MSH6: ex4A c.642C>T (Tyr) (1999)                                
PMS2: ex13 c.2253T>C (Phe)(1998),     
MLH3: ex3 c.3465+37delT (2003),         
MSH3: ex22 c.3000-22t>a, ex22 
c.3000-33_36deltgaa     
Colon cancer at age 46. Grandmother with colon cancer at age 78; 
father with colon cancer at age 71; uncle 
with colon cancer at age 64; several cases of 
polyps at early age among cousins. 
02/10 MSH6:  ex4S c.2941 A>G(Ile980Val), 
ex4D c.1164C>T (His)(1999), ex4F-G 
c.1395A>T (Ala)                                                                                            
Colon cancer at age 57. Father with colon cancer at age 70; sister 
with several polyps at age 55-60. 
02/11 MLH1: ex16 c.1856 G>A (=Lys).                                          
MSH6:  ex4S c.2941 A>G(Ile980Val) 
Sigma colon cancer at age 
42; two colon adenoma at 
age 44. 
04/10 MLH1: ex19 c.2152 C>T (His718Tyr) 
(1997)                                                                      
MSH6:  ex4Q c.2633T>C 
(Val877Ala) (1999), ex4C 
c.990A>T(Ser)                      
MLH3:ex11  c.4263G>a (p=Gln)+/+ 
Moderately differentiated 
adenocarcinoma at age 62. 
Mother dead of leukemia; father dead of colon cancer; three brothers with colon polyps between 61 and 71 years; sister with colon polyp at age 56; cousin dead of colon cancer at age 61; son with two colon polyps at age 30. 
05/3 MSH2: ex1 c.211+9C>G; 
c.1661+12G>A                                           
PMS2: ex2 c.59 G>A 
(Arg20Gln)(1995), ex7 c.780 
C>G(Ser)+/+(1995), ex12 c.2007-
7c>t(2006), ex14 c.2324 A>G 
(Asn774Ser)(1998), ex14 c.2340C>T 
(Pro)(2006)                                          
MLH3: ex1-3 c.666 G>A (Lys)  
Sigma moderately 
differentiated 
adenocarcinoma at age 53; 
descending colon 
adenocarcinoma at age 54. 
Mother with colon cancer and uterus cancer 
at age  47;  Uncle dead of sarcoma at age 42. 
05/4 MSH2: ex6 c.984C>T (p=Ala),                                                                                                      
PMS2: ex7 c.780C>G(Ser) 
+/+(1995),                   MLH3: ex1-1 
c.408T>C (p=Asp)                       
MSH3: ex4 c.693 G>A (p=Pro), ex20 
c.2732T>G (Leu910Trp) 
Left colon tubulo-villous
adenoma at age 34 and a 
right colon adenocarcinoma 
at age 42; left colon 
moderately differentiated 
mucinous adenocarcinoma at 
age  56. 
Mather dead of glioblastoma at age 63; 
uncle dead of  metachronous  colon cancer 
at age 50; uncle dead of bladder cancer at 
age 70; brother dead of glioma at age 20; 
brother with colon cancer at age 53 and his 
son with glioma at age 26; brother with 
colon cancer at age 36 and 53. 
05/7 MSH2: ex5 c.942+3_+15del 
AAAAAAAAAAAAA                                        
PMS2: ex7 c.780C>G(Ser) 
+/+(1995), ex13 c.2248G>A 
(Gly749Ser)                                         
MSH3: ex23 c.3131 
G>a(Ala1044Thr) +/+ 
Transvers and descending 
moderately differentiated 
adenocarcinoma at age 34. 
Father with colon cancer at age 36 and 
relapse at age 49 and 58; uncle dead of 
colon cancer at age 60; uncle dead of lung 
cancer at age 45 and his son with 3-4 polyps 
at age 42.  
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Figure 32. (A) Pedigree of a family with simultaneous MMR gene variants. 
Symbols and abbreviations used are denoted as fallow: Arrows, analyzed members; 
black symbol, colorectal cancer or cancer associate with HNPCC; gray symbols, 
adenomas or cancer not associated with HNPCC; CRC, colorectal cancer; Br, brain 
cancer; GU, gastric ulcer; BL, bladder cancer; Bre, breast cancer; TA, tubular 
adenoma. Number next to diagnosis denotes age at onset; black dot, not detected. 
(B) Genotypes identified in the patients of the family; patients are identified with 
their pedigree number. 
 
 
 
Figure 33. Microsatellite instability analysis for the II-5 family subject. The red 
ovals highlight the 3 unstable markers of the Bethesda panel: D2S123, BAT25 and 
BAT26. N: normal mucosa; T: tumor tissue. 
 
PATIENT
c.984 C>T 
EX6 MSH2
c.693 G>A 
EX4 MSH3
c.2732 T>G 
EX20 MSH3
c.408 T>C 
EX1 MLH3
I-3 NO YES NO YES
II-3 NO NO YES NO
II-4 NO YES NO YES
II-5 YES YES YES YES
II-6 YES YES YES YES
II-8 YES NO NO YES
II-9 NO YES NO YES
III-1 YES YES NO NO
III-2 YES YES NO YES
III-3 YES NO YES YES
III-4 YES YES NO NO
A B 
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Another interesting result of the analysis of the minor MMR genes is 
the absence of segregation with the disease for some pathogenetic 
variants identified in these genes. This condition was found in two 
patients carriers of the two variants identified in MSH6 gene. These 
are two frameshift mutations in exon 5, the c.3261_62insC, already 
described in the literature, and the new mutation c.3296_97 delTT, 
that alter the reading frame, thus resulting in truncated proteins (Fig. 
30). The pathogenicity of one of these two variants (c.3261_62insC) 
was confirmed by immunohistochemical analysis on FFPE tumor 
tissue sections showing the absence of the MSH6 protein compared 
with a lymphocyte internal control. On the other hand, MSH2 and 
MLH1 proteins were positive, as expected (Fig. 34). 
 
 
Figure 34. MSH6, MSH2 and MLH1 immunohistochemistry (IHC) in the patient 
carrier of the c.3261_62insC variant in MSH6 exon 5. (a) Absence of MSH6 in the 
colon tumor cells (arrow point); (b) IHC+ for MSH2 in the colon tumor cells (filled 
arrow head point); (c) IHC+ for MLH1 in the colon tumor cells (filled arrow head 
point). Open arrow heads point indicate IHC+ lymphocyte internal control. 
 
The first variant was identified in a subject belonging to a family not 
fulfilling the Amsterdam criteria with colorectal cancers diagnosed at 
about the age of 60 years, while the second variant was found in a 
subject belonging to a family that meets the Amsterdam criteria. 
However, these mutations do not segregate with the disease since they 
were not found in the other analyzed affected relatives.  
Finally, it was interesting to observe that the variant c. 
2049_2050insAGT in exon 4 of the MSH6 gene (Fig. 30) determines 
absence of the protein at the immunohistochemical analysis (Fig. 35), 
although it does not create a frameshift in the reading frame. This 
variant was identified in a patient with colorectal cancer diagnosed at 
the age of 46 years, belonging to a family that meets the Bethesda 
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criteria. This mutation segregates with the disease because it was 
found in the affected brother. Therefore, the insertion c. 
2049_2050insAGT can be considered a pathogenetic variant. 
 
Figure 35. MLH1, MSH2 and MSH6 immunohistochemistry (IHC) in the patient 
carrier of c. 2049_2050insAGT variant in the MSH6 exon 4. (1) IHC+ for MLH1 in 
the colon tumor cells (filled arrow head point) 10X; (2) IHC+ for MSH2 in the colon 
tumor cells (filled arrow head point) 10X and (3) 20X; (4) IHC- for MSH6 in the 
colon tumor cells (arrow point) 10X and (5) 20X. Open arrow head point indicate 
IHC+ lymphocyte internal control. 
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4. DISCUSSION/CONCLUSIONS 
 
The results obtained in this study provide new perspectives for the 
molecular diagnosis of Lynch syndrome. 
Mutational analysis performed on the minor MMR genes, MSH6, 
PMS2, MLH3 and MSH3, was performed on 64 families with clinical 
diagnosis of HNPCC, selected by specific criteria on the basis of  
phenotypic features. We analyzed families that meet the Amsterdam I 
and II criteria (37%) and those that do not meet these criteria, showing 
an atypical phenotype (about 70%); these include familial cases with 
early age of onset of the disease and low microsatellite instability or 
cases in which the cancer developed at a young age, with a high 
degree of microsatellite instability. All these families were negative 
for point mutations and large rearrangements in two major MMR 
genes, namely hMLH1 and hMSH2. 
Literature data report a large number of families with clinical 
diagnosis of Lynch syndrome, in which no mutations have been found 
in the major MMR genes. The Lynch-like phenotype may result from 
germline mutations in other genes such as the colon cancer 
susceptibility genes TGFβ-RII, the APC gene variants, I1307K and 
E1317Q, MYH, AXIN2 and EXO1. Of these, only EXO1 could have 
a role in the DNA repair complex, determining high microsatellite 
instability. Nevertheless, the literature data suggest that EXO1 is not a 
gene associated with Lynch syndrome (Thompson E., 2004). 
Therefore, our research was focused on the mutation detection in the 
minor MMR genes, assuming the low-penetrance of these genes. 
(Loukola A., 2000;Yang G., 2004; Silva FC., 2009). We carried out 
the mutation detection at the level of the four minor MMR genes.  
Since each minor MMR gene has a repetitive sequence of 8 or more 
nucleotides in its coding region, they can be considered themselves as 
target genes of the mutator phenotype that accelerates the mutation 
rate in other oncogene and oncosuppressor genes.  
A total of 77 variants were identified in minor MMR genes, the 
majority of these (about 87%) were classified variants of uncertain 
significance. Most of the mutations were found in MSH6 and PMS2 
genes (27 and 21 variants, respectively), while a lower percentage of 
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variants were present in the remaining minor genes MLH3 and MSH3 
(15 and 13, respectively). These results were in accordance with 
literature data that show mutations in the MSH6 gene in about 10% of 
families with Lynch syndrome and mutations in the PMS2 and MLH3 
genes in about 5% of cases. In order to understand the contribution of 
mutations in the minor genes to the disease development, it is 
necessary to take into account the role of each protein in the mismatch 
repair complex. 
Although MSH6 and MSH3 have a redundant role in the repair 
complex, several studies carried out in mice and in yeast demonstate 
that the absence of MSH6 can not be fully compensated by the action 
of MSH3. Studies of Edelmann et colleagues (1997) have shown that 
homozygous mice for MSH6 missense mutations were unable to 
repair any type of defect, because the dysfunctional mutated protein 
was still preserved within the cell, competing with MSH3 to the 
MSH2 binding, and thus interfering with the MSH2-MSH3 complex 
to repair insertions or deletions. This suggests that missense mutations 
in MSH6, without the MSH3 loss, determines a severe phenotype. 
Instead, the loss of the MSH6 protein (nonsense mutations) associated 
with the severe phenotype could result from a secondary mutation in 
MSH3 gene. In this regard, we demonstrate that the two mutations 
identified in the MSH6 gene, the c.3261_62insC and the c.3296_97 
delTT both identified in exon 5, do not segregate with the disease in 
the family, in the spite of their apparent pathological role due to the 
loss of the protein as also confirmed by the negative 
immunohistochemical analysis on tumor tissue. Therefore, our study 
was directed towards the mutation detection in other minor MMR 
genes PMS2, MLH3 and MSH3, that confirmed the simultaneous 
presence of other variants in the subject with a severe phenotype 
compared to other family members who showed an attenuated 
phenotype. Moreover, we do not exclude the presence of mutations in 
other genes not examined in this study, that could contribute to the 
disease development in synergistic manner with the MMR variants.  
It is interesting to observe that the variant c. 2049_2050insAGT in 
exon 4 of MSH6 gene determines the absence of the protein at the 
immunohistochemical analysis, although it do not create a frameshift 
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in the reading frame. This variant was identified in a patient who 
meets the Bethesda criteria, and it segregates with the disease in the 
family. We hypothesize that this variant causes an aberrant structural 
modification of the protein that induce its degradation in the cell. 
Therefore, the insertion c. 2049_2050insAGT could be considered a 
pathogenetic variant. 
Moreover, the most important result of this mutational analysis on 
minor MMR genes was the simultaneous presence of multiple 
molecular alterations in different genes or in the same gene in the 
DNA of a same patient. Although some MLH1 and MSH2 mutations 
are responsible for a monogenic transmission in tumor development, 
we proposed that some (or all) of the identified variants in the minor 
MMR genes constitute low penetrance alleles, with an additive effect 
on the risk of the disease (Duraturo F., 2011). Two recent studies on 
the yeast genome have shown that weak alleles of the complex MMR 
cause a weak mutator phenotype but, when they interact with each 
other, a strong mutator phenotype is observed (Martinez SL., 2010; 
Kumar, 2011). This hypothesis is supported by an exhaustive 
molecular analysis of one of the 64 subjects analyzed in this study. In 
this family (Fig. 31, Results section), the simultaneous presence of 
several low penetrance variants was associated with a severe 
phenotype that could suggest an additive effect of these mutations in 
predisposition of cancer development. 
Furthermore, we tried to define a pathogenetic role for numerous 
variants of uncertain significance (VUS), identified in the minor 
MMR genes in this study, using a multifactorial likelihood model 
according to literature data (Colon cancer Family Registry 2009, 
InSiGHT Variant Interpretatioin Committee 2011). This approach is 
based on both phenotipic and functional features (Introduction 
section). We demonstrate that none of the above criteria, including 
functional assays, is an indicator of pathogenicity, if considered 
individually; it is necessary that a combination of these strategies be 
used to assess an exhaustive evaluation of the pathogenicity of 
uncertain variants. Among these criteria, the segregation analysis 
should be considered the "gold standard" for the validation of any type 
59 
Discussion 
of in vitro analysis (Couch FJ, 2008; SE Plon, 2008; R. Hofstra, 
2008; Goldgar DE, 2008).  
The multifactorial likelihood model was also used to study other 
several VUS identified in major MMR genes, MLH1 and MSH2, in 
order to assign them a pathogenetic significance in Lynch syndrome. 
This multivariate approach allowed us to demonstrate a likely 
genotype-phenotype correlation for several variants. In this study, the 
analysis of 3 variants in MLH1 gene and 1 variant in MSH2 gene 
were reported. 
In particular, we observed that the missense mutation, c.304G>A in 
exon 3 of MLH1 gene, behaves as a truncating mutation at the level of 
the cDNA. Therefore, this can be considered as a class 5 variant and 
not as a class 3 variant, as reported in the literature.  
Similarly, the study of the silent mutation c.438A>G in exon 5 of 
MLH1 gene has shown a likely role in the development of the disease 
as it determines aberrant effects on splicing process and consequently 
at the level of the final transcript. 
Finally, we analyzed two variants identified in the 3’-UTR of MLH1 
and MSH2 genes, according to the literature that suggests to explain 
the unsolved genotype-phenotype correlations in Lynch syndrome by 
analysing MMR gene regions not routinely investigated such as the 
promoter and the 5’- and the 3’-untraslated sites with respect to 
canonical coding regions (Carethers JM., 2014; Boland R., 2013). 
In particular, the c.*30_32delTTC (3’UTR) in the MLH1 gene, yet 
described in literature database as class-1 of uncertain significance, 
results in a significant reduction in both levels of the transcript and the 
protein. In silico analysis by computational tool TRANSFAC shows 
that this deletion could destroy the binding site for a transcriptional 
regulation factor, a glucocorticoid receptor (GR) that acts in the 
inflammatory response. This variant has been the subject of several 
literature studies that reported data in agreement with those obtained 
in this thesis. In particular, Mao et al. showed that the region where 
the mutation falls is a putative binding site for miR-422a that is 
disrupted by the 3-nucleotide deletion, suggesting a likely role for 
miR-422a in regulating expression of MLH1. The Authors 
demonstrated a reciprocal feedback regulation mechanism between 
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MLH1 and miR-422a where the MLH1-PMS2 heterodimer stimulate 
the conversion of pri-miR-422a to pre-miR-422a, while this miRNA 
down-regulates mutLα levels by suppressing MLH1 expression 
through base pairing with the MLH1 3’-UTR region (fig. 36) (Mao 
G., 2012).  
 
 
Figure 36. Model for reciprocal feedback regulation between MLH1 and miR-422a 
proposed by Mao G. et al. (Cell Res 2012, 22:973-985). 
 
A previous study highlights that this mutation confers a mutator 
phenotype and mismatch repair deficiency in patients with relapsed 
leukemia, because a significant reduction in the steady-state level of 
MLH1 mRNA and protein, and a consequently defective MMR 
activity, as demonstrated by luciferase assay, was present. The 
secondary structure analysis of the WT and MT 3-UTR of MLH1 
showed that the TTC-deletion lies in a large stem-loop structure. The 
deletion of 3-nucleotide in the region reduced the size of the stem-
loop and created a new smaller stem-loop (Fig.37) (Mao G., 2008).  
The alteration of this stem-loop may prevent the binding to trans-
acting protein factors (TF) or microRNAs and instead may allow the 
interaction with different regulatory factors with a negative effect on 
the stability of the MLH1 transcript. In our study, this variant was 
always associated with a severe phenotype (MSI-H), when it was in 
association with the variant c.454-51t>c, described in literature as 
class-1 variant. 
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Figure 37. Predicted folding of MLH1 WT and MT 3’-UTR. Secondary structure of 
human MLH1 WT (A) or MT (B) 3'-UTR was predicted by the Mfold algorithm 
(http://bioweb.pasteur.fr/seqanal/interfaces/mfold.html). Arrows indicate changes in 
structures between WT and MT mRNAs (Mao G. et al. JBC, 2008, 283: 3211-3216) 
 
The computational analysis performed by the HSF algorithm for this 
intronic variant showed a likely deleterious effect on the splicing 
process. Therefore, we may hypothesize a pathogenic additive effect 
for these two genetic alterations. 
The multivariate analysis of the other 3’UTR variant, the c.*226A>G 
in MSH2 gene, was also very interesting in order to understand the 
correlation with the disease phenotype. In our study, this variant is 
associated with both typical Lynch Syndrome features (CRC and 
endometrial atrophy) and atypical phenotype such as Hodgkin 
Lymphoma. 
In contrast with the reduction observed with the MLH1 3’-UTR 
variant, the MSH2 3’UTR gene mutation determined increased 
mRNA and protein levels, as confirmed by immunoistochemistry 
analysis and by functional luciferase assay. 
In silico analysis by TRANSFAC software showed this region as a 
putative binding site for four trans-acting protein factors (TF) with 
transcriptional repressor role, expecially for ZNF333 (zinc-finger 
protein 333), and CDP (cut-like homeobox1 protein). The mutation 
would prevent the interaction with all these factors. 
Furthermore, we identified also two potential miRNA, hsa-miR-137 
and hsa-miR-4795-3p, able to bind the region where the mutation 
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falls, by two in silico prediction tools, TargetScan and miRanda. The 
mutation consisting in a single base substitution would prevent the 
binding with these above regulating factors without, however, favor 
the interaction with other factors. The loss of regulation for the MSH2 
transcript would explain the observed overexpression that does not 
enhance genome stability but promotes hypermutability, as described 
in the Introduction section. In particular, we hypothesize that this 
effect is related to the loss of MSH2 down regulation by the has-miR-
137 according to the literature data that indicate this miRNA as a 
tumor suppressor in the colon, inhibiting cell proliferation. Moreover, 
hsa-miR-137 is preferentially expressed in the epithelial cells of 
normal colonic mucosa, while low has-miR-137 expression has been 
observed in the adenomatous polyps and CRC tissues (Balaguer F., 
2010). This condition would be enhanced by the mutation that would 
prevent any type of binding. Of course, this our assumption needs 
further study. In this study, we began to investigated the association 
between hsa-miR-137 and the MSH2 expression, by transfection of 
ectopic precursor hsa-miR-137 in two colorectal cancer cell lines, 
HT29 and SW480, that express high and low levels of the miR-137, 
respectively (Balaguer F., 2010). The qRT-PCR performed on the 
MSH2 mRNA after 48h from transfection showed decreased levels of 
the MSH2 transcript, especially in the HT29 cells, suggesting a 
possible role for this miRNA in MSH2 regulating expression.  
In conclusion, this study allowed to clarify the genotype-phenotype 
correlations in Lynch syndrome, demonstrating the importance of a 
multifactorial likelihood analytical approach, also in order to 
understand the molecular mechanisms that regulate the MMR protein 
and their putative prognostic and therapeutic implications in Lynch 
Syndrome. Moreover, the simultaneous presence of molecular 
alterations in several genes analyzed (major and minor MMR genes) 
could suggest an additive effect of these mutations in the 
predisposition to develop cancer, in contrast with the classical 
monogenic transmission and in favor of a polygenic inheritance, 
although further studies on other familial cases are needed to confirm 
this hypothesis. 
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